

Chimeric Antigen Receptor T Cells in Refractory B-Cell

New England Journal of Medicine

377, 2545-2554

DOI: [10.1056/nejmoa1708566](https://doi.org/10.1056/nejmoa1708566)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Milestone for CAR T Cells. <i>New England Journal of Medicine</i> , 2017, 377, 2593-2596.	13.9	52
3	Engineering chimeric antigen receptor-T cells for cancer treatment. <i>Molecular Cancer</i> , 2018, 17, 32.	7.9	57
4	Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1135-1141.	2.0	60
5	Cancer Immunotherapy 2017 (Paris, France). Progress and challenges. <i>Bulletin Du Cancer</i> , 2018, 105, 537-541.	0.6	1
6	Have we found the right patient population for transplantation in follicular lymphoma?. <i>Cancer</i> , 2018, 124, 2484-2487.	2.0	0
7	Beginning the CAR T cell therapy revolution in the US and EU. <i>Current Research in Translational Medicine</i> , 2018, 66, 62-64.	1.2	24
8	Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations. <i>Current Research in Translational Medicine</i> , 2018, 66, 59-61.	1.2	7
9	CAR T cell therapy for B-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 135-146.	0.7	39
10	Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma. <i>Current Research in Translational Medicine</i> , 2018, 66, 43-49.	1.2	45
11	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 218-218.	12.5	114
12	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1266-1272.	0.6	106
13	The EURECART project as a prototype model for CAR T cell immunotherapy in Europe. <i>European Journal of Immunology</i> , 2018, 48, 216-219.	1.6	3
14	Next-generation immunotherapies for lymphoma: one foot in the future. <i>Annals of Oncology</i> , 2018, 29, 588-601.	0.6	13
15	Favourable outcomes with CAR T cells. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 65-65.	12.5	7
16	Chimeric antigen receptor-modified T cells: CD19 and the road beyond. <i>Blood</i> , 2018, 131, 2621-2629.	0.6	126
18	Immunotherapy and Prevention of Pancreatic Cancer. <i>Trends in Cancer</i> , 2018, 4, 418-428.	3.8	296
19	Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. <i>Blood</i> , 2018, 132, 245-253.	0.6	52
20	Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector. <i>Molecular Therapy</i> , 2018, 26, 1447-1456.	3.7	77

#	ARTICLE	IF	CITATIONS
21	Is cell therapy the answer for hematological malignancies?. Expert Opinion on Biological Therapy, 2018, 18, 495-497.	1.4	0
22	Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma. Advances in Cell and Gene Therapy, 2018, 1, e23.	0.6	1
23	Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 400-414.	1.8	63
24	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2018, 36, 2845-2853.	0.8	313
25	CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients. Turkish Journal of Haematology, 2018, 35, 217-228.	0.2	9
27	Biologic and Immunotherapy Developments in Advanced Hepatocellular Carcinoma. , 2018, , .		0
29	New Treatment Options in Advanced Stage Follicular Lymphoma. HemaSphere, 2018, 2, e156.	1.2	1
30	Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. Current Opinion in Lipidology, 2018, 29, 381-388.	1.2	8
31	The role of allogeneic stem cell transplantation in T-cell lymphoma. Current Opinion in Oncology, 2018, 30, 301-307.	1.1	5
32	Immunotherapy in non-Hodgkin lymphoma. Annals of Lymphoma, 0, 2, 9-9.	4.5	0
33	Cytokine release syndrome and neurotoxicity after <sc>CD</sc>19 chimeric antigen receptorâ€modified (<sc>CAR</sc>â€) T cell therapy. British Journal of Haematology, 2018, 183, 364-374.	1.2	131
34	Making CAR T Cells a Solid Option for Solid Tumors. Frontiers in Immunology, 2018, 9, 2593.	2.2	147
35	Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. Science China Life Sciences, 2018, 61, 1320-1332.	2.3	11
36	Immune Therapies for Lymphomas: A Disruptive Technology With Opportunities for Radiation. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1396-1399.	0.4	0
37	CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge. Frontiers in Immunology, 2018, 9, 2460.	2.2	101
38	Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Frontiers in Microbiology, 2018, 9, 3158.	1.5	66
39	Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective. Critical Care Medicine, 2018, 46, 1402-1410.	0.4	56
40	Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. International Journal of Molecular Sciences, 2018, 19, 4118.	1.8	7

#	ARTICLE	IF	CITATIONS
41	Lymphoma in Adolescents and Young Adults. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 285-300.	1.0	7
42	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
43	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. <i>Frontiers in Immunology</i> , 2018, 9, 2740.	2.2	58
44	Novel therapeutic agents for relapsed classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 105-112.	1.2	16
45	Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting. <i>Cancer Cell</i> , 2018, 34, 596-610.e11.	7.7	102
46	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 351.	1.3	71
47	Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas. <i>Cancers</i> , 2018, 10, 339.	1.7	13
48	An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1829-1834.	0.9	2
49	Allogeneic CAR-T Cells: More than Ease of Access?. <i>Cells</i> , 2018, 7, 155.	1.8	129
50	Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 484-493.	1.2	7
51	The Potential of CAR T Cell Therapy in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2166.	2.2	92
52	Double hit and double expressors in lymphoma: Definition and treatment. <i>Cancer</i> , 2018, 124, 4622-4632.	2.0	121
53	Chimeric antigen receptor modified T cells for cancer treatment. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 225-243.	0.9	10
54	Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 534-542.	1.2	14
55	Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. <i>CNS Drugs</i> , 2018, 32, 1091-1101.	2.7	175
56	Engineering CAR-T Cells for Improved Function Against Solid Tumors. <i>Frontiers in Immunology</i> , 2018, 9, 2493.	2.2	67
57	Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor T-cell therapy in B-cell non-Hodgkin lymphomas. <i>Cytotherapy</i> , 2018, 20, 1415-1418.	0.3	45
58	Harnessing the immune system in glioblastoma. <i>British Journal of Cancer</i> , 2018, 119, 1171-1181.	2.9	138

#	ARTICLE	IF	CITATIONS
59	A CHIP mutation to battle cancer: potential or hazard for cardiovascular disease?. Cardiovascular Research, 2018, 114, e96-e98.	1.8	0
60	In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Molecular Therapy, 2018, 26, 2727-2737.	3.7	180
61	Stem cell transplantation for amyotrophic lateral sclerosis. Current Opinion in Neurology, 2018, 31, 655-661.	1.8	23
62	New developments in immunotherapy for lymphoma. Cancer Biology and Medicine, 2018, 15, 189.	1.4	24
63	Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors. Human Gene Therapy, 2018, 29, 1083-1097.	1.4	11
64	Sequencing of therapies in relapsed follicular lymphoma. Hematology American Society of Hematology Education Program, 2018, 2018, 189-193.	0.9	9
65	Novel immunotherapy approaches to follicular lymphoma. Hematology American Society of Hematology Education Program, 2018, 2018, 194-199.	0.9	8
66	Novel therapies for relapsed/refractory aggressive lymphomas. Hematology American Society of Hematology Education Program, 2018, 2018, 75-82.	0.9	9
67	A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Advances, 2018, 2, 517-528.	2.5	56
68	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nature Medicine, 2018, 24, 739-748.	15.2	947
69	Follicular Lymphoma: Past, Present, and Future. Current Treatment Options in Oncology, 2018, 19, 32.	1.3	10
70	How I manage patients with relapsed/refractory diffuse large B cell lymphoma. British Journal of Haematology, 2018, 182, 633-643.	1.2	127
71	Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. Molecular Therapy, 2018, 26, 1401-1403.	3.7	14
72	CAR T cells induce a complete response in refractory Burkitt Lymphoma. Bone Marrow Transplantation, 2018, 53, 1583-1585.	1.3	25
73	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018, 558, 307-312.	13.7	574
74	My burning issues in aggressive Non Hodgkin's Lymphoma. Memo - Magazine of European Medical Oncology, 2018, 11, 109-111.	0.3	0
75	CAR-T in the clinic: drive with care. Gene Therapy, 2018, 25, 157-161.	2.3	10
76	T Lymphocyte-Based Cancer Immunotherapeutics. International Review of Cell and Molecular Biology, 2018, 341, 201-276.	1.6	22

#	ARTICLE	IF	CITATIONS
77	Exploiting Viruses to Treat Diseases. <i>New England Journal of Medicine</i> , 2018, 379, 194-196.	13.9	6
78	CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 601-611.	1.9	25
79	Chimeric Antigen Receptor Therapy. <i>New England Journal of Medicine</i> , 2018, 379, 64-73.	13.9	1,488
80	Cousins at work: How combining medical with optical imaging enhances in vivo cell tracking. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 102, 40-50.	1.2	34
81	Chimeric antigen receptor T (CAR T) cells: another cancer therapy with potential applications in kidney disease and transplantation?. <i>Kidney International</i> , 2018, 94, 4-6.	2.6	8
82	Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. <i>Blood</i> , 2018, 132, 1022-1026.	0.6	58
83	Cytokine release syndrome. , 2018, 6, 56.		1,055
84	Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 877-882.	0.9	95
85	Management of relapsed/refractory DLBCL. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 209-216.	0.7	91
86	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. <i>Frontiers in Immunology</i> , 2018, 9, 1740.	2.2	155
87	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2211-2215.	2.0	9
88	Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1007-1017.	0.9	45
89	The promise of CAR T-cell therapy in aggressive B-cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 293-298.	0.7	44
90	Cancer immunotherapy with CAR-T cells " behold the future. <i>Clinical Medicine</i> , 2018, 18, 324-328.	0.8	32
91	Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. <i>Frontiers in Immunology</i> , 2018, 9, 1104.	2.2	95
92	Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 193.	1.3	12
93	Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. <i>Molecular Cancer</i> , 2018, 17, 91.	7.9	60
94	Prenatal Regeneration in Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2018, 93, 673-675.	1.4	3

#	ARTICLE	IF	CITATIONS
95	Current and future therapeutic approaches for the treatment of follicular lymphoma. Expert Review of Anticancer Therapy, 2018, 18, 931-941.	1.1	0
96	CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. Molecular Therapy, 2018, 26, 1906-1920.	3.7	38
97	Tumour tamed by transfer of one T cell. Nature, 2018, 558, 193-195.	13.7	2
98	CARs versus BiTEs: A Comparison between T Cell's Redirection Strategies for Cancer Treatment. Cancer Discovery, 2018, 8, 924-934.	7.7	173
99	Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood, 2018, 132, 681-688.	0.6	23
100	Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mammalian Genome, 2018, 29, 739-756.	1.0	33
101	Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opinion on Biological Therapy, 2018, 18, 905-910.	1.4	89
102	Novel Approaches in Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 875-890.	0.9	4
103	Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis. Blood, 2018, 131, 2630-2639.	0.6	9
104	Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomarker Research, 2018, 6, 4.	2.8	184
105	CIMT 2018: Pushing frontiers in cancer immunotherapy Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines and Immunotherapeutics, 2018, 14, 2864-2873.	1.4	1
106	Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks. Current Oncology Reports, 2018, 20, 75.	1.8	55
107	A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clinical Cancer Research, 2018, 24, 6185-6194.	3.2	177
108	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood, 2018, 132, 1495-1506.	0.6	100
109	Immunotherapy in aggressive B-cell lymphomas. Best Practice and Research in Clinical Haematology, 2018, 31, 299-305.	0.7	3
110	Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. Journal of Hematology and Oncology, 2018, 11, 102.	6.9	63
111	Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma. Current Hematologic Malignancy Reports, 2018, 13, 356-368.	1.2	14
112	Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. Oncoimmunology, 2018, 7, e1488565.	2.1	41

#	ARTICLE	IF	CITATIONS
113	Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia. Expert Review of Anticancer Therapy, 2018, 18, 959-971.	1.1	19
114	Cancer Immunotherapy. Glycobiology, 2018, 28, 638-639.	1.3	5
115	Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discovery, 2018, 8, 1219-1226.	7.7	661
116	Immune Gene Therapy and the International Conference on Lymphocyte Engineering (ICLE 2018). Human Gene Therapy, 2018, 29, vii-ix.	1.4	0
117	Chimeric antigen receptor T cell therapy: a hematological success story. Memo - Magazine of European Medical Oncology, 2018, 11, 116-121.	0.3	6
118	Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood, 2018, 132, 777-781.	0.6	105
119	Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. Bone Marrow Transplantation, 2019, 54, 17-25.	1.3	4
120	Cancer immune therapy for lymphoid malignancies: recent advances. Seminars in Immunopathology, 2019, 41, 111-124.	2.8	15
121	Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells. Journal of Visualized Experiments, 2019, , .	0.2	24
122	CAR-T " and a side order of IgG, to go? " Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Reviews, 2019, 38, 100596.	2.8	109
123	Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys. Journal of Onco-Nephrology, 2019, 3, 131-143.	0.3	0
125	T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression. OncoImmunology, 2019, 8, e1621676.	2.1	17
126	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Molecular Therapy, 2019, 27, 1919-1929.	3.7	220
127	An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment. Frontiers in Immunology, 2019, 10, 1691.	2.2	70
128	Expression of carcinoma, apoptosis, and cell "death" related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatric Blood and Cancer, 2019, 66, e27783.	0.8	11
129	<p>Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date</p>. OncoTargets and Therapy, 2019, Volume 12, 4543-4554.	1.0	6
130	Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 393-419.	2.7	45
131	Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment. Current Treatment Options in Neurology, 2019, 21, 40.	0.7	65

#	ARTICLE	IF	CITATIONS
132	Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1012-1021.	0.4	105
133	T-cell therapies for T-cell lymphoma. <i>Cytotherapy</i> , 2019, 21, 935-942.	0.3	10
134	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e344-e351.	2.0	59
135	Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. <i>Scientific Reports</i> , 2019, 9, 10634.	1.6	53
136	Rapid relapse of large B-cell lymphoma after CD19 directed CAR T-cell therapy due to CD19 antigen loss. <i>American Journal of Hematology</i> , 2019, 94, E273-E275.	2.0	29
137	Allogenic Transplant for Non-Hodgkin Lymphoma. , 2019, , 209-229.		0
138	Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e443-e451.	5.1	66
139	Immunobiology of chimeric antigen receptor T cells and novel designs. <i>Immunological Reviews</i> , 2019, 290, 100-113.	2.8	16
140	CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma. <i>Scientific Reports</i> , 2019, 9, 9211.	1.6	38
141	Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases. <i>Pharmaceutical Medicine</i> , 2019, 33, 83-88.	1.0	2
142	Myocarditis in the Setting of Cancer Therapeutics. <i>Circulation</i> , 2019, 140, 80-91.	1.6	278
143	Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience. <i>Oncology</i> , 2019, 97, 59-74.	0.9	13
144	CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 626-635.	0.6	59
145	Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 687-705.	0.9	6
146	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , 2019, 134, 636-640.	0.6	127
147	Contemporary management of nodal and primary splenic marginal zone lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 1011-1022.	1.0	2
148	Cost burden of diffuse large B-cell lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 645-661.	0.7	14
149	CAR-T cell therapy: a potential new strategy against prostate cancer. , 2019, 7, 258.		61

#	ARTICLE	IF	CITATIONS
150	Have treatment protocols for primary CNS lymphoma advanced in the past 10 years?. Expert Review of Anticancer Therapy, 2019, 19, 909-915.	1.1	15
151	Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays. Advanced Science, 2019, 6, 1901829.	5.6	19
152	Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics, 2019, 9, 7924-7947.	4.6	77
153	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell, 2019, 36, 471-482.	7.7	280
154	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia, 2019, 33, 2767-2778.	3.3	47
155	Maintaining a fit Tâ€cell compartment: lymphoma treatment sequencing in the era of chimeric antigen receptor Tâ€cell therapies. Internal Medicine Journal, 2019, 49, 1338-1338.	0.5	1
156	How Should We Determine the Value of CAR T-Cell Therapy?. AMA Journal of Ethics, 2019, 21, E844-851.	0.4	11
158	Pembrolizumab for the treatment of diffuse large B-cell lymphoma. Expert Opinion on Biological Therapy, 2019, 19, 1119-1126.	1.4	14
159	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
160	Improving cancer immunotherapy through nanotechnology. Nature Reviews Cancer, 2019, 19, 587-602.	12.8	426
161	The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 4320.	1.8	43
162	Hematological malignancies and molecular targeting therapy. European Journal of Pharmacology, 2019, 862, 172641.	1.7	44
163	B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma. Molecular Therapy - Oncolytics, 2019, 14, 279-287.	2.0	120
164	Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine, 2019, 25, 1341-1355.	15.2	400
165	Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. JCI Insight, 2019, 4, .	2.3	46
166	Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy. Cancer Immunology Research, 2019, 7, 1824-1836.	1.6	40
167	Genetically engineered T cells for cancer immunotherapy. Signal Transduction and Targeted Therapy, 2019, 4, 35.	7.1	153
168	Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptorâ€™BTK Signaling Pathway. Journal of Immunology, 2019, 203, 2043-2048.	0.4	20

#	ARTICLE	IF	CITATIONS
169	Conventional CARs versus modular CARs. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1713-1719.	2.0	37
170	Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy. <i>Scientific Reports</i> , 2019, 9, 13293.	1.6	20
171	CAR T cell viability release testing and clinical outcomes: is there a lower limit?. <i>Blood</i> , 2019, 134, 1873-1875.	0.6	24
172	T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 7340-7350.	3.2	32
174	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	67
175	Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 909-918.	1.0	7
176	Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 47-55.	1.2	12
177	Engineering and Design of Chimeric Antigen Receptors. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 145-156.	1.8	281
179	An introduction to chimeric antigen receptor (CAR) T cell immunotherapy for human cancer. <i>American Journal of Hematology</i> , 2019, 94, S3-S9.	2.0	340
180	Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer. <i>Cancers</i> , 2019, 11, 696.	1.7	23
181	Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy. <i>Journal of Immunological Methods</i> , 2019, 472, 55-64.	0.6	17
182	DLL3: an emerging target in small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 61.	6.9	115
183	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2839.	1.8	34
184	Autoreactive T-Lymphocytes in Inflammatory Skin Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1198.	2.2	48
185	Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir. <i>Current Opinion in Virology</i> , 2019, 38, 21-30.	2.6	28
186	CD123 CAR T cells for the treatment of myelodysplastic syndrome. <i>Experimental Hematology</i> , 2019, 74, 52-63.e3.	0.2	25
187	Immune cell therapy for hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 52.	6.9	90
188	The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies. <i>Cytotherapy</i> , 2019, 21, 769-781.	0.3	17

#	ARTICLE	IF	CITATIONS
189	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 2105-2119.	0.8	155
190	A review of chimeric antigen receptor T-cells in lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 551-561.	1.0	11
191	Diagnosis and management of follicular lymphoma: A comprehensive review. <i>European Journal of Haematology</i> , 2019, 103, 152-163.	1.1	29
192	Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 1230-1243.	2.5	43
193	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2019, 33, 2540-2544.	3.3	26
194	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFC.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e026644.	0.8	27
195	The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 433-444.	1.8	200
196	The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.		66
197	CAR-Based Approaches to Cutaneous T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 259.	1.3	15
198	Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression. <i>Leukemia and Lymphoma</i> , 2019, 60, 2814-2816.	0.6	5
199	Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma. , 2019, , 167-183.		1
200	Heterogeneity and coexistence of oncogenic mechanisms involved in HCV-associated B-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 156-171.	2.0	8
201	Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. <i>Frontiers in Immunology</i> , 2019, 10, 957.	2.2	88
202	A safe and potent anti-CD19 CAR T cell therapy. <i>Nature Medicine</i> , 2019, 25, 947-953.	15.2	314
203	Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9543-9551.	3.3	266
204	Tisagenlecleucel in Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 1585-1586.	13.9	13
205	Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell Therapy. <i>Clinical and Translational Science</i> , 2019, 12, 343-349.	1.5	50
206	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984158.	1.1	160

#	ARTICLE	IF	CITATIONS
207	Neurological toxicities associated with chimeric antigen receptor T-cell therapy. <i>Brain</i> , 2019, 142, 1334-1348.	3.7	166
208	Engineering advanced cancer therapies with synthetic biology. <i>Nature Reviews Cancer</i> , 2019, 19, 187-195.	12.8	46
209	Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. <i>Visceral Medicine</i> , 2019, 35, 28-37.	0.5	7
210	Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	178
211	Engineering Protein Delivery Depots for Cancer Immunotherapy. <i>Bioconjugate Chemistry</i> , 2019, 30, 515-524.	1.8	20
212	Challenges of driving CD30-directed CAR-T cells to the clinic. <i>BMC Cancer</i> , 2019, 19, 203.	1.1	41
213	What CAR Will Win the CD19 Race?. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 498-506.	1.9	8
214	Optimizing Precision Medicine for Public Health. <i>Frontiers in Public Health</i> , 2019, 7, 42.	1.3	58
215	Advances, Challenges, and Perspectives in Translational Stem Cell Therapy for Amyotrophic Lateral Sclerosis. <i>Molecular Neurobiology</i> , 2019, 56, 6703-6715.	1.9	24
216	Recent landmark studies in follicular lymphoma. <i>Blood Reviews</i> , 2019, 35, 68-80.	2.8	9
217	The Emergence of Universal Immune Receptor T Cell Therapy for Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 176.	1.3	64
218	Chimeric Antigen Receptorâ€“Engineered T Cell Therapy in Lymphoma. <i>Current Oncology Reports</i> , 2019, 21, 38.	1.8	20
219	<p>Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 323-335.	0.9	110
220	Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies. <i>Trends in Immunology</i> , 2019, 40, 274-278.	2.9	7
221	Germinal centerâ€“derived lymphomas: The darkest side of humoral immunity. <i>Immunological Reviews</i> , 2019, 288, 214-239.	2.8	113
222	Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2019, 37, 834-849.	0.8	66
223	CARâ€“T cell therapy for nonâ€“Hodgkin lymphomas: A new treatment paradigm. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e54.	0.6	8
224	Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1926-1933.	0.6	3

#	ARTICLE	IF	CITATIONS
225	CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies. <i>AAPS Journal</i> , 2019, 21, 50.	2.2	13
226	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 4014-4025.	3.2	110
227	Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. <i>Journal of Experimental Medicine</i> , 2019, 216, 1038-1049.	4.2	109
228	Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells. <i>Cytotherapy</i> , 2019, 21, 278-288.	0.3	9
229	Chemotherapy and Beyond. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 289-309.	1.9	34
230	CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 328-335.	0.8	31
231	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	1.3	218
232	Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. <i>Expert Review of Hematology</i> , 2019, 12, 195-205.	1.0	63
233	Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. <i>Frontiers in Immunology</i> , 2019, 10, 263.	2.2	69
234	Cellular immunotherapy for acute myeloid leukemia: How specific should it be?. <i>Blood Reviews</i> , 2019, 35, 18-31.	2.8	23
235	Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. <i>American Journal of Hematology</i> , 2019, 94, S28-S33.	2.0	35
236	Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 1142-1157.	1.2	29
237	CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1126-1132.	1.4	42
238	CAR T cells: The future is already present. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 281-286.	0.1	0
239	Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies. <i>Transfusion</i> , 2019, 59, 1773-1780.	0.8	29
240	Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches. <i>Molecular Therapy - Oncolytics</i> , 2019, 12, 124-137.	2.0	62
241	CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions. <i>Journal of the National Cancer Institute</i> , 2019, 111, 646-654.	3.0	126
242	Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. <i>Journal of Biological Chemistry</i> , 2019, 294, 5430-5437.	1.6	114

#	ARTICLE	IF	CITATIONS
243	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , 2019, 133, 1876-1887.	0.6	230
244	Toxicities of CD19 CAR T cell immunotherapy. <i>American Journal of Hematology</i> , 2019, 94, S42-S49.	2.0	102
245	Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1092-1098.	2.0	79
246	Engineered T Cell Therapies from a Drug Development Viewpoint. <i>Engineering</i> , 2019, 5, 140-149.	3.2	8
247	Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. <i>Transfusion Medicine Reviews</i> , 2019, 33, 98-110.	0.9	124
248	From fiction to science: clinical potentials and regulatory considerations of gene editing. <i>Clinical and Translational Medicine</i> , 2019, 8, 27.	1.7	26
249	Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. <i>Blood Advances</i> , 2019, 3, 2022-2034.	2.5	58
250	Construction of chimeric antigen receptor-modified T cells targeting EpCAM and assessment of their anti-tumor effect on cancer cells. <i>Molecular Medicine Reports</i> , 2019, 20, 2355-2364.	1.1	14
252	Immunologic treatment strategies in mantle cell lymphoma: checkpoint inhibitors, chimeric antigen receptor (CAR) T-cells, and bispecific T-cell engager (BiTE) molecules. <i>Annals of Lymphoma</i> , 0, 3, 6-6.	4.5	1
253	Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review. <i>Future Oncology</i> , 2019, 15, 4235-4246.	1.1	5
254	Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. <i>Blood Advances</i> , 2019, 3, 2230-2236.	2.5	59
255	Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. <i>Blood Advances</i> , 2019, 3, 2491-2498.	2.5	68
256	CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. <i>Blood</i> , 2019, 134, 1510-1516.	0.6	52
257	Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. <i>Blood</i> , 2019, 134, 2149-2158.	0.6	194
258	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	2.5	92
259	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. <i>Blood Advances</i> , 2019, 3, 3248-3260.	2.5	76
260	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , 2019, 3, 3590-3601.	2.5	52
261	The case for CAR T-cell therapy in follicular lymphomas. <i>Blood</i> , 2019, 134, 577-578.	0.6	16

#	ARTICLE	IF	CITATIONS
264	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6986-6994.	3.2	77
265	Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy. <i>Cancers</i> , 2019, 11, 1832.	1.7	38
266	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. <i>Clinical Cancer Research</i> , 2019, 25, 7046-7057.	3.2	56
267	Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma. <i>Medicine (United States)</i> , 2019, 98, e17506.	0.4	12
268	Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 223-230.	1.0	15
269	Treatment of high-risk follicular lymphoma. <i>HemaSphere</i> , 2019, 3, 85-87.	1.2	0
270	Management of T-Cell Engaging Immunotherapy Complications. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 223-230.	1.0	15
271	Enterotoxins can support CAR T cells against solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25229-25235.	3.3	16
272	Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor T cell manufacture. <i>Cytotherapy</i> , 2019, 21, 1198-1205.	0.3	23
273	Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6223.	1.8	88
274	CAR T Cell Therapy for Hematological Malignancies. <i>Current Medical Science</i> , 2019, 39, 874-882.	0.7	22
275	T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments. <i>Current Opinion in Oncology</i> , 2019, 31, 430-438.	1.1	6
276	Current landscape for chimeric antigen receptor T cells in lymphomas. <i>Current Opinion in Hematology</i> , 2019, 26, 421-426.	1.2	1
277	Current status and hurdles for CAR-T cell immune therapy. <i>Blood Science</i> , 2019, 1, 148-155.	0.4	5
278	Antibiotics for the Treatment of Staphylococcal Infections in the Obstetric Patient. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 790-803.	0.6	0
279	CAR T Cell Toxicity: Current Management and Future Directions. <i>HemaSphere</i> , 2019, 3, e186.	1.2	121
280	In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR T Cell Therapy. <i>HemaSphere</i> , 2019, 3, e191.	1.2	80
281	Invariant NKT cells as a platform for CAR immunotherapy and prevention of acute Graft-versus-Host Disease. <i>HemaSphere</i> , 2019, 3, 31-34.	1.2	6

#	ARTICLE	IF	CITATIONS
282	Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities: A Review for Perioperative Physicians. <i>Anesthesia and Analgesia</i> , 2019, 129, 434-441.	1.1	11
283	Follicular lymphoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 83.	18.1	148
284	Advances in T-cell Immunotherapies. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 825-837.	0.9	5
285	Redirecting T cells to treat solid pediatric cancers. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 611-624.	2.7	3
286	Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. <i>Drugs in Context</i> , 2019, 8, 1-14.	1.0	29
288	The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 86-93.	2.0	21
289	Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e123-e127.	2.0	220
290	Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. <i>BioDrugs</i> , 2019, 33, 45-60.	2.2	61
291	Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. <i>Bone Marrow Transplantation</i> , 2019, 54, 969-972.	1.3	13
292	Effective effectors: How T cells access and infiltrate the central nervous system. , 2019, 197, 52-60.		11
293	Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. <i>Clinical Chemistry</i> , 2019, 65, 519-529.	1.5	4
294	Cancer Immunotherapy: Beyond Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2019, 3, 55-75.	2.3	102
295	Entering the Modern Era of Gene Therapy. <i>Annual Review of Medicine</i> , 2019, 70, 273-288.	5.0	311
296	Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. <i>Blood Reviews</i> , 2019, 34, 45-55.	2.8	570
297	The acceleration of CAR-T therapy in non-Hodgkin lymphoma. <i>Hematological Oncology</i> , 2019, 37, 233-239.	0.8	4
298	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. <i>Blood</i> , 2019, 133, 697-709.	0.6	408
299	Adoptive cellular therapies: the current landscape. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 449-461.	1.4	261
300	Delivery technologies for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 175-196.	21.5	1,562

#	ARTICLE	IF	CITATIONS
301	Advances in cellular and humoral immunotherapy â€” implications for the treatment of poor risk childhood, adolescent, and young adult Bâ€”cell nonâ€”Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 1055-1070.	1.2	16
302	Chimeric antigen receptor modified T cell therapy in B cell nonâ€”Hodgkin lymphomas. <i>American Journal of Hematology</i> , 2019, 94, S18-S23.	2.0	19
303	C�lulas CAR T: el futuro ya es presente. <i>Medicina Cl�nica</i> , 2019, 152, 281-286.	0.3	1
304	Emerging Cellular Therapies for Cancer. <i>Annual Review of Immunology</i> , 2019, 37, 145-171.	9.5	263
305	Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 3-24.	0.0	0
306	Chimeric Antigen Receptor T Cells for Lymphomas: Methods, Data, and Challenges. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 93-108.	0.0	0
307	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 45-56.	13.9	2,594
308	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1â€”2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	5.1	1,467
309	CD19-directed CAR T cells gain traction. <i>Lancet Oncology</i> , The, 2019, 20, 2-3.	5.1	19
310	Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e155-e162.	2.0	56
312	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 393-399.	1.3	29
313	Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. <i>Transfusion Medicine Reviews</i> , 2020, 34, 29-33.	0.9	81
314	The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2020, 25, e321-e327.	1.9	81
315	Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. , 2020, 205, 107419.		81
316	CAR-T Cell Therapy for Lymphoma: How Does Radiation Therapy Fit In?. <i>Practical Radiation Oncology</i> , 2020, 10, e155-e158.	1.1	8
317	Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. <i>Regenerative Engineering and Translational Medicine</i> , 2020, 6, 29-49.	1.6	16
318	Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy. <i>Advances in Biological Regulation</i> , 2020, 75, 100663.	1.4	12
319	Outcomes in patients with aggressive Bâ€”cell nonâ€”Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	2.0	18

#	ARTICLE	IF	CITATIONS
320	New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances. <i>Hematological Oncology</i> , 2020, 38, 22-33.	0.8	7
322	Immunoglobulin replacement and quality of life after CAR T-cell therapy – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e7.	5.1	3
323	IL-18-dependent and independent pathways account for IL-18-enhanced antitumor ability of CAR-T cells. <i>FASEB Journal</i> , 2020, 34, 1768-1782.	0.2	15
326	Immunoglobulin replacement and quality of life after CAR T-cell therapy. <i>Lancet Oncology</i> , The, 2020, 21, e6.	5.1	3
327	A brief history of human disease genetics. <i>Nature</i> , 2020, 577, 179-189.	13.7	441
328	A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	70
329	Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. <i>Nature Communications</i> , 2020, 11, 219.	5.8	167
330	Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis. <i>Chinese Medical Journal</i> , 2020, 133, 74-85.	0.9	18
331	Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 234-243.e10.	0.2	0
332	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 147-167.	12.5	786
333	Advances in relapsed/refractory follicular lymphoma therapeutics. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e74.	0.6	1
334	Important aspects of T-cell collection by apheresis for manufacturing chimeric antigen receptor T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e75.	0.6	6
335	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
336	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e77-e85.	2.0	41
337	Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. <i>Current Opinion in Hematology</i> , 2020, 27, 41-48.	1.2	14
338	Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications – The Role of Molecular Dynamics Simulation. <i>Biotechnology Journal</i> , 2020, 15, e1900368.	1.8	22
339	Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. <i>Critical Care Medicine</i> , 2020, 48, 10-21.	0.4	42
340	Follicular lymphoma: 2020 update on diagnosis and management. <i>American Journal of Hematology</i> , 2020, 95, 316-327.	2.0	140

#	ARTICLE	IF	CITATIONS
341	Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 799-807.	0.6	10
342	What a headache! Double-hit lymphoma with CNS recurrence – Role of chimeric antigen receptor (CAR) T-cell therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 757-762.	0.6	4
343	Follicular Lymphoma. , 2020, , .		0
344	Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential. <i>Blood Reviews</i> , 2020, 41, 100645.	2.8	21
345	Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). <i>British Journal of Haematology</i> , 2020, 188, 240-248.	1.2	17
346	B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis. <i>European Journal of Haematology</i> , 2020, 104, 318-327.	1.1	41
347	CAR T-Cell: Cell Processing Laboratory Considerations. , 2020, , 17-28.		1
348	Peri-CAR T-Cell Management. , 2020, , 29-44.		1
349	Management of Cytokine Release Syndrome. , 2020, , 45-64.		1
350	Special Considerations for ICU Management of Patients Receiving CAR Therapy. , 2020, , 65-81.		0
351	Neurotoxicities After CAR T-Cell Immunotherapy. , 2020, , 83-105.		7
352	CAR T-Cell Therapy for CNS Malignancies. , 2020, , 165-198.		0
353	Chimeric Antigen Receptor Therapies. , 2020, , 349-359.		0
354	Advances in chimeric antigen receptor T cells. <i>Current Opinion in Hematology</i> , 2020, 27, 368-377.	1.2	24
355	Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source. <i>Blood Advances</i> , 2020, 4, 4292-4295.	2.5	9
356	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3805-3815.	0.8	129
357	Resident Memory T Cells and Their Effect on Cancer. <i>Vaccines</i> , 2020, 8, 562.	2.1	13
358	Production and characterization of haploidentical CD19 CAR T cells: Validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 44-51.	0.7	4

#	ARTICLE	IF	CITATIONS
359	Novel anti-GD2 CAR-T cells exhibit superior cytotoxicity against neuroblastoma. <i>European Journal of Inflammation</i> , 2020, 18, 205873922096119.	0.2	1
360	Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. <i>Cell</i> , 2020, 183, 126-142.e17.	13.5	269
361	Targeting Innate Immunity to Treat Cancer. <i>Cancers</i> , 2020, 12, 2723.	1.7	1
362	Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 1594.	1.3	46
363	A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. <i>Neurologic Clinics</i> , 2020, 38, 953-963.	0.8	14
364	Iatrogenic Neuropathology of Systemic Therapies. <i>Surgical Pathology Clinics</i> , 2020, 13, 331-342.	0.7	4
365	Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	9
366	Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells. <i>Scientific Reports</i> , 2020, 10, 17884.	1.6	14
367	Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. <i>Oncolimmunology</i> , 2020, 9, 1825177.	2.1	26
368	Potential strategies against resistance to CAR T-cell therapy in haematological malignancies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096296.	1.4	7
369	Point mutation in <i>CD19</i> facilitates immune escape of B cell lymphoma from CAR-T cell therapy. , 2020, 8, e001150.		47
370	Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. <i>Cancers</i> , 2020, 12, 2820.	1.7	13
371	A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation. <i>Molecular Therapy</i> , 2020, 28, 2564-2576.	3.7	14
372	Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation. <i>Nano-Micro Letters</i> , 2020, 12, 185.	14.4	42
373	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4898-4911.	2.5	238
374	From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?. <i>Vaccines</i> , 2020, 8, 597.	2.1	8
375	A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Advances in Therapy</i> , 2020, 37, 4877-4893.	1.3	8
376	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. <i>Urologic Clinics of North America</i> , 2020, 47, 487-510.	0.8	10

#	ARTICLE	IF	CITATIONS
377	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nature Medicine</i> , 2020, 26, 1569-1575.	15.2	266
378	Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies. <i>Cancers</i> , 2020, 12, 1915.	1.7	30
379	Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives. <i>Cancers</i> , 2020, 12, 1889.	1.7	36
380	Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17543-17550.	3.3	54
381	Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy. <i>British Journal of Haematology</i> , 2020, 191, 126-129.	1.2	15
382	Immunotherapies and Combination Strategies for Immuno-Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5009.	1.8	63
383	Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. <i>Experimental Hematology</i> , 2020, 88, 7-14.e3.	0.2	21
384	How to Combine the Two Landmark Treatment Methods—Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?. <i>Frontiers in Immunology</i> , 2020, 11, 611710.	2.2	14
385	Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. <i>Journal of Clinical Medicine</i> , 2020, 9, 3626.	1.0	4
386	Gene Modified CART-T Cellular Therapy for Hematologic Malignancies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8655.	1.8	13
387	Using single-cell analysis to predict CAR T cell outcomes. <i>Nature Medicine</i> , 2020, 26, 1813-1814.	15.2	2
388	An analysis of genetic targets for guiding clinical management of follicular lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 1361-1372.	1.0	0
389	<i>Neospora caninum</i> : a new class of biopharmaceuticals in the therapeutic arsenal against cancer. , 2020, 8, e001242.		6
390	Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. <i>Frontiers in Immunology</i> , 2020, 11, 564099.	2.2	32
391	Haploidentical Stem Cell Transplantation in Lymphomas—Expectations and Pitfalls. <i>Journal of Clinical Medicine</i> , 2020, 9, 3589.	1.0	6
392	Circumventing Myeloid-Derived Suppressor Cell-Mediated Immunosuppression Using an Oxygen-Generated and -Economized Nanoplatfom. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 55723-55736.	4.0	28
393	<p></p>Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12163-12168.	1.0	4
394	C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. <i>Blood Advances</i> , 2020, 4, 5858-5862.	2.5	12

#	ARTICLE	IF	CITATIONS
395	Novel targets in aggressive lymphoma. Hematology American Society of Hematology Education Program, 2020, 2020, 101-106.	0.9	9
396	Immunotherapy with cells (article not eligible for CME credit). Hematology American Society of Hematology Education Program, 2020, 2020, 590-597.	0.9	1
397	Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. Frontiers in Oncology, 2020, 10, 1362.	1.3	45
398	Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. Immunity, 2020, 53, 456-470.e6.	6.6	83
399	A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes. Frontiers in Immunology, 2020, 11, 1704.	2.2	21
400	A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. Molecular Therapy, 2020, 28, 2577-2592.	3.7	58
401	Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. JAMA Neurology, 2020, 77, 1536.	4.5	68
402	Immune-Checkpoint Blockade Therapy in Lymphoma. International Journal of Molecular Sciences, 2020, 21, 5456.	1.8	24
403	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. Journal of Clinical Oncology, 2020, 38, 3794-3804.	0.8	235
404	Acute life-threatening toxicity from CAR T-cell therapy. Intensive Care Medicine, 2020, 46, 1723-1726.	3.9	14
405	From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment. Frontiers in Immunology, 2020, 11, 1423.	2.2	5
406	CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 1243.	1.3	63
407	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy, 2020, 5, 134.	7.1	84
408	Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell, 2020, 38, 473-488.	7.7	342
409	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica, 2021, 106, 2667-2672.	1.7	92
410	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. Expert Review of Hematology, 2020, 13, 851-869.	1.0	2
411	Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. Pancreatology, 2020, 20, 394-408.	0.5	10
412	Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy. Frontiers of Medicine, 2020, 14, 786-791.	1.5	6

#	ARTICLE	IF	CITATIONS
413	VAV1-overexpressing YT cells display improved cytotoxicity against malignant cells. <i>Biotechnology and Applied Biochemistry</i> , 2020, 68, 849-855.	1.4	2
414	Manufacturing and Management of CAR T-Cell Therapy in COVID-19's Time: Central Versus Point of Care Proposals. <i>Frontiers in Immunology</i> , 2020, 11, 573179.	2.2	12
415	Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway. <i>Oncotargets and Therapies</i> , 2020, 9, 1824643.	2.1	24
416	Successful myeloablative unrelated bone marrow transplantation for relapsed intravascular large B cell lymphoma after autologous peripheral blood stem cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 3067-3069.	0.8	2
417	How I treat adverse effects of CAR-T cell therapy. <i>ESMO Open</i> , 2020, 4, e000746.	2.0	19
418	Cervical Cancer: Emerging Immune Landscape and Treatment. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8037-8047.	1.0	32
419	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. <i>Npj Systems Biology and Applications</i> , 2020, 6, 28.	1.4	61
420	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. <i>EMBO Molecular Medicine</i> , 2020, 12, e10865.	3.3	104
421	Beyond CAR T cells: Engineered V β 2 T cells to fight solid tumors. <i>Immunological Reviews</i> , 2020, 298, 117-133.	2.8	9
422	Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	3
423	Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 1973.	2.2	148
424	Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2523.	1.7	27
425	CD19-directed CAR T-cell therapy in B-cell NHL. <i>Current Opinion in Oncology</i> , 2020, 32, 408-417.	1.1	26
426	Overhauling CAR T Cells to Improve Efficacy, Safety and Cost. <i>Cancers</i> , 2020, 12, 2360.	1.7	9
427	Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective. <i>Journal of Medical Economics</i> , 2020, 23, 1321-1329.	1.0	20
428	New agents and regimens for diffuse large B cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 175.	6.9	79
429	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 3837.	1.7	9
430	Hematopoietic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. <i>Frontiers in Oncology</i> , 2020, 10, 608916.	1.3	13

#	ARTICLE	IF	CITATIONS
431	An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. <i>Cell Chemical Biology</i> , 2021, 28, 802-812.e6.	2.5	25
432	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 620312.	2.2	21
433	Function and evolution of the prototypic CD28 \uparrow and 4-1BB \uparrow chimeric antigen receptors. <i>Immuno-Oncology Technology</i> , 2020, 8, 2-11.	0.2	8
434	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. <i>Respiration</i> , 2020, 99, 903-929.	1.2	18
435	Practical aspects of building a new immunotherapy program: the future of cell therapy. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 579-584.	0.9	2
436	Precision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy. <i>Vaccines</i> , 2020, 8, 732.	2.1	4
437	Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	10
438	Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. <i>Scientific Reports</i> , 2020, 10, 18997.	1.6	59
439	Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. <i>Haematologica</i> , 2020, 106, 173-184.	1.7	25
440	Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. <i>Cancers</i> , 2020, 12, 1075.	1.7	57
441	Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 408-420.	2.0	57
442	Biomarkers in individualized management of chimeric antigen receptor T cell therapy. <i>Biomarker Research</i> , 2020, 8, 13.	2.8	23
444	CAR-Transduced Natural Killer Cells. <i>New England Journal of Medicine</i> , 2020, 382, 1865-1867.	13.9	1
445	Toward α CD19 β CD28 \uparrow allogeneic CAR T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e86.	0.6	20
446	Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress. <i>Annals of Hematology</i> , 2020, 99, 1681-1699.	0.8	5
447	Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e89-e106.	1.8	17
448	Aptamer-T Cell Targeted Therapy for Tumor Treatment Using Sugar Metabolism and Click Chemistry. <i>ACS Chemical Biology</i> , 2020, 15, 1554-1565.	1.6	28
449	Adoptive cellular immunotherapy of tumors via effective CpG delivery to dendritic cells using dendrimer-entrapped gold nanoparticles as a gene vector. <i>Journal of Materials Chemistry B</i> , 2020, 8, 5052-5063.	2.9	30

#	ARTICLE	IF	CITATIONS
450	Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers. <i>Journal of Emergency Medicine</i> , 2020, 59, 61-74.	0.3	5
451	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1575-1580.	2.0	20
452	Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series. <i>Blood Advances</i> , 2020, 4, 1859-1866.	2.5	7
453	Identification of a moderate affinity CD22 binding peptide and <i>in vitro</i> optimization of peptide-targeted nanoparticles for selective uptake by CD22+ B-cell malignancies. <i>Nanoscale</i> , 2020, 12, 11672-11683.	2.8	10
454	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.	0.6	62
455	Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1736-1743.	1.0	16
456	Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 661-667.	0.2	8
457	Regional Injection of CAR-T Cells for the Treatment of Refractory and Recurrent Diffuse Large B Cell Lymphoma: A Case Report. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 333.	1.8	7
458	Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. <i>Leukemia</i> , 2020, 34, 3055-3059.	3.3	23
459	CAR T-cell immunotherapy of B-cell malignancy: the story so far. , 2020, 8, 251513552092716.	1.4	30
460	Development of CAR-T cell therapies for multiple myeloma. <i>Leukemia</i> , 2020, 34, 2317-2332.	3.3	68
461	A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3886.	1.8	23
462	CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3906.	1.8	50
463	CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. <i>Frontiers in Oncology</i> , 2020, 10, 849.	1.3	62
464	Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 575-587.	0.9	19
465	Treating central nervous system lymphoma in the era of precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 275-281.	0.4	1
466	The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology. <i>Frontiers in Immunology</i> , 2020, 11, 1608.	2.2	57
467	Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. <i>Blood</i> , 2020, 136, 1632-1644.	0.6	119

#	ARTICLE	IF	CITATIONS
468	Neurologic Toxicities of Cancer Immunotherapies: a Review. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 27.	2.0	17
469	Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2020, 11, 1128.	2.2	29
470	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
471	Cardiovascular Effects of CAR T Cell Therapy. <i>JACC: CardioOncology</i> , 2020, 2, 193-203.	1.7	84
472	CAR T Cell Therapy-Related Cardiovascular Outcomes and Management. <i>JACC: CardioOncology</i> , 2020, 2, 97-109.	1.7	73
473	Chimeric antigen receptor T-cell therapies: Optimising the dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1678-1689.	1.1	25
474	Advances in Developing CAR T-Cell Therapy for HIV Cure. <i>Frontiers in Immunology</i> , 2020, 11, 361.	2.2	42
475	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 15.	7.1	66
476	Tuning the Antigen Density Requirement for CAR T-cell Activity. <i>Cancer Discovery</i> , 2020, 10, 702-723.	7.7	296
477	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1247-1256.	2.0	139
478	In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery. <i>Scientific Reports</i> , 2020, 10, 4544.	1.6	20
479	Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor. <i>Journal of the American Chemical Society</i> , 2020, 142, 6554-6568.	6.6	36
480	Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. <i>Acta Oncologica</i> , 2020, 59, 766-774.	0.8	9
481	Immunomodulators in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 28.	1.3	4
482	Ethical Considerations in Therapeutic Clinical Trials Involving Novel Human Germline-Editing Technology. <i>CRISPR Journal</i> , 2020, 3, 18-26.	1.4	6
483	Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells. <i>Molecular Therapy</i> , 2020, 28, 1392-1416.	3.7	44
484	Human chimeric antigen receptor macrophages for cancer immunotherapy. <i>Nature Biotechnology</i> , 2020, 38, 947-953.	9.4	692
485	Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 448-454.	1.8	28

#	ARTICLE	IF	CITATIONS
486	T cell-engaging therapies – BiTEs and beyond. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 418-434.	12.5	296
487	Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer. <i>Cancers</i> , 2020, 12, 842.	1.7	21
488	Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. <i>Blood</i> , 2020, 135, 17-27.	0.6	191
489	Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 147.	2.2	39
490	Next-generation CAR T cells to overcome current drawbacks. <i>International Journal of Hematology</i> , 2020, 114, 532-543.	0.7	7
491	Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective. <i>Frontiers in Oncology</i> , 2020, 10, 885.	1.3	20
492	Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. <i>Frontiers in Immunology</i> , 2020, 11, 1217.	2.2	69
493	Immune and Cell Therapy in Non-Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 269-277.	1.0	4
494	Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. <i>Blood</i> , 2020, 136, 1722-1734.	0.6	37
495	Immunogenomic Landscape of Hematological Malignancies. <i>Cancer Cell</i> , 2020, 38, 380-399.e13.	7.7	109
496	Cellular Therapy in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 701-714.	0.9	1
497	Improving the Odds. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e173-e174.	2.0	1
498	How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. <i>Blood</i> , 2020, 136, 925-935.	0.6	158
499	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2871-2883.	2.5	134
500	Navigating the narrow bridge to CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 2884-2885.	2.5	13
501	Organoid Models of Tumor Immunology. <i>Trends in Immunology</i> , 2020, 41, 652-664.	2.9	210
502	The Contribution of Epigenetics to Cancer Immunotherapy. <i>Trends in Immunology</i> , 2020, 41, 676-691.	2.9	133
504	Controversies in the Treatment of Follicular Lymphoma. <i>HemaSphere</i> , 2020, 4, e317.	1.2	15

#	ARTICLE	IF	CITATIONS
505	Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer. <i>Advanced Science</i> , 2020, 7, 1903164.	5.6	22
506	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. <i>Cancer</i> , 2020, 126, 1837-1855.	2.0	20
507	CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	49
508	Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. <i>Frontiers in Oncology</i> , 2020, 9, 1529.	1.3	23
509	Cryoablation and immunotherapy of cancer. <i>Current Opinion in Biotechnology</i> , 2020, 65, 60-64.	3.3	36
510	Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. <i>Journal of Critical Care</i> , 2020, 57, 124-129.	1.0	25
511	Head and Neck Dystonia Following Chimeric Antigen Receptor T Cell Immunotherapy: A Case Report. <i>Laryngoscope</i> , 2020, 130, E863-E864.	1.1	2
512	CAR T cells: continuation in a revolution of immunotherapy. <i>Lancet Oncology</i> , The, 2020, 21, e168-e178.	5.1	204
513	Recent Advances in Allogeneic CAR-T Cells. <i>Biomolecules</i> , 2020, 10, 263.	1.8	68
514	Implications of T cell receptor biology on the development of new T cell therapies for cancer. <i>Immunotherapy</i> , 2020, 12, 89-103.	1.0	9
515	Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. <i>American Journal of Kidney Diseases</i> , 2020, 76, 63-71.	2.1	74
516	Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients. <i>Blood Cancer Journal</i> , 2020, 10, 8.	2.8	32
517	Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 270-280.	15.2	182
518	Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e013755.	1.6	37
519	The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. <i>Cytotherapy</i> , 2020, 22, 57-69.	0.3	70
520	CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 359-368.	1.8	22
521	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , 2020, 382, 545-553.	13.9	1,252
522	Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 683.	2.2	102

#	ARTICLE	IF	CITATIONS
523	C-reactive protein: not always a reliable marker of ongoing cytokine release syndrome in CAR-T therapy following IL-6 blockade. <i>Leukemia and Lymphoma</i> , 2020, 61, 2280-2282.	0.6	0
524	The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptorâ€T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. <i>Cytotherapy</i> , 2020, 22, 214-226.	0.3	29
525	Bypassing the Immunosuppression of Myeloidâ€Derived Suppressor Cells by Reversing Tumor Hypoxia Using a Plateletâ€Inspired Platform. <i>Advanced Functional Materials</i> , 2020, 30, 2000189.	7.8	54
526	Bâ€cell maturation antigenâ€specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. <i>International Journal of Cancer</i> , 2020, 147, 2029-2041.	2.3	10
528	Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy. <i>Acta Biomaterialia</i> , 2020, 109, 21-36.	4.1	34
529	The Emerging Landscape of Immune Cell Therapies. <i>Cell</i> , 2020, 181, 46-62.	13.5	247
530	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. , 2020, 8, e000148.		42
531	Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy. <i>Cancer Immunology Research</i> , 2020, 8, 926-936.	1.6	73
532	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. <i>Clinical and Experimental Medicine</i> , 2020, 20, 469-480.	1.9	8
533	How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. <i>Frontiers in Physiology</i> , 2020, 11, 154.	1.3	27
534	Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. <i>Cells</i> , 2020, 9, 983.	1.8	10
536	Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e183-e191.	2.0	25
537	Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). <i>BMJ Open</i> , 2020, 10, e034629.	0.8	26
538	Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies. <i>Cell Transplantation</i> , 2020, 29, 096368972091943.	1.2	16
539	The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1342-1351.	2.2	5
540	Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. <i>Blood</i> , 2020, 135, 597-609.	0.6	134
541	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. <i>Blood Advances</i> , 2020, 4, 560-572.	2.5	88
542	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020, 4, 676-686.	2.5	101

#	ARTICLE	IF	CITATIONS
543	A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells. <i>Leukemia</i> , 2021, 35, 119-129.	3.3	15
544	Chimeric antigen receptor T-cell therapy toxicities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2414-2424.	1.1	19
545	CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells. <i>Haematologica</i> , 2021, 106, 987-999.	1.7	42
546	Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 978-986.	1.7	141
547	Emerging role of microbiota in immunomodulation and cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2021, 70, 37-52.	4.3	19
548	The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 30-37.	1.3	5
549	Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 90-113.	2.7	24
550	Developing cell therapies as drug products. <i>British Journal of Pharmacology</i> , 2021, 178, 262-279.	2.7	6
551	CAR-T cells: Early successes in blood cancer and challenges in solid tumors. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1129-1147.	5.7	47
552	Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. <i>Molecular Therapy</i> , 2021, 29, 433-441.	3.7	22
553	Cardiotoxic mechanisms of cancer immunotherapy – A systematic review. <i>International Journal of Cardiology</i> , 2021, 323, 179-187.	0.8	31
554	Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. <i>Annual Review of Medicine</i> , 2021, 72, 365-382.	5.0	34
555	Nanotechnology-Based CAR-T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, .	7.8	13
556	Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103096.	2.0	10
557	Clinical development of CAR T cell therapy in China: 2020 update. <i>Cellular and Molecular Immunology</i> , 2021, 18, 792-804.	4.8	50
558	Pharmacology of Chimeric Antigen Receptor-Modified T Cells. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 805-829.	4.2	7
559	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , 2021, 137, 323-335.	0.6	111
560	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. <i>Infection</i> , 2021, 49, 215-231.	2.3	63

#	ARTICLE	IF	CITATIONS
561	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. <i>Molecular Therapy</i> , 2021, 29, 636-644.	3.7	80
562	Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989â€”2016. <i>Leukemia</i> , 2021, 35, 1683-1695.	3.3	8
563	Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy â€” what are we doing; where are we going?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 627-637.	1.4	25
564	Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation. <i>Blood Reviews</i> , 2021, 47, 100779.	2.8	2
565	A metabolic switch to memory CAR T cells: Implications for cancer treatment. <i>Cancer Letters</i> , 2021, 500, 107-118.	3.2	21
566	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. <i>Critical Care Clinics</i> , 2021, 37, 47-67.	1.0	5
567	CARâ€™ TREK through the lymphoma universe, to boldly go where no other therapy has gone before. <i>British Journal of Haematology</i> , 2021, 193, 449-465.	1.2	17
568	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 298-308.	0.6	127
569	Chimeric antigen receptor Tâ€™cell therapy after allogeneic stem cell transplant for relapsed/refractory large Bâ€™cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 212-216.	1.2	14
570	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1134-1143.	1.3	17
571	Prolonged neurotoxicity in a lymphoma patient after CD19â€™directed CAR Tâ€™cell therapy: A case report and brief review of the literature. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, e104.	0.6	1
572	Blueprint for cancer research: Critical gaps and opportunities. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 107-139.	157.7	47
573	CAR T Cell and BiTE Therapyâ€™New Therapies, New Risks?. <i>Current Cardiovascular Risk Reports</i> , 2021, 15, 1.	0.8	1
574	PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. <i>Human Immunology</i> , 2021, 82, 130-138.	1.2	25
575	Current status of cancer immunotherapy for gynecologic malignancies. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 167-172.	0.6	16
576	Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. <i>Annals of Oncology</i> , 2021, 32, 34-48.	0.6	231
577	Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 429-437.	1.0	1
578	Kinetics of immune reconstitution after antiâ€™CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 250-258.	0.7	14

#	ARTICLE	IF	CITATIONS
579	T cell immunobiology and cytokine storm of COVID-19. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12989.	1.3	77
580	Neurological updates: neurological complications of CAR-T therapy. <i>Journal of Neurology</i> , 2021, 268, 1544-1554.	1.8	37
581	CAR T cell therapies for patients with multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 71-84.	12.5	156
582	Introduction on Treatment for Infectious Diseases and Immunological Disorders. , 2021, , .		0
583	Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 1-7.	1.2	9
584	High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 112-116.	1.2	0
585	How we treat mature B-cell neoplasms (indolent B-cell lymphomas). <i>Journal of Hematology and Oncology</i> , 2021, 14, 5.	6.9	16
586	Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies. <i>Cell Transplantation</i> , 2021, 30, 096368972110255.	1.2	16
587	Significance of trogocytosis and exosome-mediated transport in establishing and maintaining the tumor microenvironment in lymphoid malignancies. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 192-201.	0.3	4
588	Recent advances and discoveries in the mechanisms and functions of CAR T cells. <i>Nature Reviews Cancer</i> , 2021, 21, 145-161.	12.8	436
589	CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1538-1552.	3.2	39
590	An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1025-1034.	1.4	4
591	Imaging of cell-based therapy using ⁸⁹ Zr-oxine <i>ex vivo</i> cell labeling for positron emission tomography. <i>Nanotheranostics</i> , 2021, 5, 27-35.	2.7	20
592	CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells. <i>Nature Communications</i> , 2021, 12, 240.	5.8	28
593	Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. <i>Oncolmmunology</i> , 2021, 10, 1945804.	2.1	16
594	Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective. <i>Journal of Medical Economics</i> , 2021, 24, 637-653.	1.0	9
595	Genome editing of immune cells using CRISPR/Cas9. <i>BMB Reports</i> , 2021, 54, 59-69.	1.1	8
596	CAR-T Technology and New Opportunities for Tumor Treatment. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 149-156.	0.1	1

#	ARTICLE	IF	CITATIONS
597	Preclinical development of CD126 CAR-T cells with broad antitumor activity. <i>Blood Cancer Journal</i> , 2021, 11, 3.	2.8	16
598	Treatment and resistance of glioblastoma to CAR T-cell immunotherapies. , 2021, , 453-471.		0
599	Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids. , 2021, , .		0
600	InÂvitro T lymphopoiesis. , 2021, , 23-53.		0
601	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. , 2021, , 1-23.		0
602	The use of immunotherapy for treatment of chemoresistant ovarian cancer. , 2021, , 79-96.		0
603	Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1026.	1.8	31
604	The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110177.	1.1	3
605	Generating CAR T cells from tumor-infiltrating lymphocytes. , 2021, 9, 251513552110171.	1.4	6
606	Adult Diffuse Astrocytic and Oligodendroglial Tumors. <i>Neurosurgery</i> , 2021, 89, 737-749.	0.6	1
607	Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 618387.	2.2	38
608	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. <i>Journal of Clinical Oncology</i> , 2021, 39, 456-466.	0.8	21
609	Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 846-858.	1.9	13
610	Novel Therapy Approaches to Follicular Lymphoma. <i>Drugs</i> , 2021, 81, 453-469.	4.9	4
611	Hematopoietic Stem Cell- and Induced Pluripotent Stem Cell-Derived CAR-NK Cells as Reliable Cell-Based Therapy Solutions. <i>Stem Cells Translational Medicine</i> , 2021, 10, 987-995.	1.6	23
612	The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 617583.	2.2	20
613	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	12.5	31
614	Harnessing the power of foot-and-mouth-disease virus for targeting integrin alpha-v beta-6 for the therapy of cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 737-744.	2.5	10

#	ARTICLE	IF	CITATIONS
615	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. <i>Journal of Clinical Oncology</i> , 2021, 39, 487-498.	0.8	27
616	Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. <i>New England Journal of Medicine</i> , 2021, 384, 673-674.	13.9	178
617	Engineering advanced logic and distributed computing in human CAR immune cells. <i>Nature Communications</i> , 2021, 12, 792.	5.8	68
618	La terapia con células CAR-T. <i>Medicina Clínica</i> , 2021, 156, 123-125.	0.3	0
619	CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1642-1650.	1.3	14
620	Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase I/2 trial. <i>Clinical and Translational Oncology</i> , 2021, 23, 1620-1629.	1.2	2
621	Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells. <i>HemaSphere</i> , 2021, 5, e533.	1.2	8
622	Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 608485.	2.2	4
623	Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 346-360.	0.8	3
624	Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. <i>Cancer Science</i> , 2021, 112, 1357-1368.	1.7	19
625	Cell therapies in the clinic. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10214.	3.9	68
626	Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 476-486.	0.8	8
627	CAR-T cell therapy. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 123-125.	0.1	0
628	Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 72-81.	1.2	7
629	Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors. <i>Advanced Functional Materials</i> , 2021, 31, 2009489.	7.8	29
630	Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. <i>Frontiers in Immunology</i> , 2021, 12, 627764.	2.2	28
631	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	0.8	25
632	Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV. <i>PLoS ONE</i> , 2021, 16, e0248973.	1.1	10

#	ARTICLE	IF	CITATIONS
633	Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 535-541.	1.8	5
634	Macrophages as a Double-Edged Weapon: The Use of Macrophages in Cancer Immunotherapy and Understanding the Cross-Talk Between Macrophages and Cancer. <i>DNA and Cell Biology</i> , 2021, 40, 429-440.	0.9	7
635	Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1085-1095.	4.8	74
636	Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model. <i>Acta Oncologica</i> , 2021, 60, 735-743.	0.8	2
637	Adoptive Cellular Therapy for Solid Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 57-65.	1.8	10
638	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , 2021, 11, 648655.	1.3	19
639	Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, , .	0.7	1
640	Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity. , 2021, 9, e001536.		23
641	The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. <i>Frontiers in Immunology</i> , 2021, 12, 639818.	2.2	60
642	Circulating low CD4+/CD8+ ratio is associated with poor prognosis in Waldenstrom macroglobulinemia patients. <i>Annals of Hematology</i> , 2021, 100, 995-1002.	0.8	5
643	Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2021, 13, 345-357.	1.0	6
644	Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 640082.	2.2	64
645	InÂvivo CART cell imaging: Paving the way for success in CART cell therapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 625-633.	2.0	14
646	TCR Î² chainâ€‘directed bispecific antibodies for the treatment of T cell cancers. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	30
647	A single-chain antibody generation system yielding CAR-T cells with superior antitumor function. <i>Communications Biology</i> , 2021, 4, 273.	2.0	14
648	Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy. <i>Journal of Immunology</i> , 2021, 206, 1561-1568.	0.4	36
649	Chimeric antigen receptor T cell therapy in oncology â€‘ Pipeline at a glance: Analysis of the ClinicalTrials.gov database. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103239.	2.0	21
650	How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 134-142.	1.0	1

#	ARTICLE	IF	CITATIONS
651	Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 183-192.	0.9	1
652	A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. <i>Science Immunology</i> , 2021, 6, .	5.6	105
653	Neurotoxicity Biology and Management. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 126-133.	1.0	7
654	Improving and Maintaining Responses in Pediatric Bâ€‘Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptorâ€‘T Cell Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 151-158.	1.0	0
655	Current Challenges in Hematology: Awareness, Prevention, Equity. <i>Frontiers in Oncology</i> , 2021, 11, 653020.	1.3	1
656	Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. <i>JCI Insight</i> , 2021, 6, .	2.3	18
657	State-of-Art of Cellular Therapy for Acute Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4590.	1.8	12
658	Chimeric Antigen Receptorâ€‘Modified T Cells and T Cellâ€‘Engaging Bispecific Antibodies: Different Tools for the Same Job. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 218-233.	1.2	4
659	Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer. <i>Cancers</i> , 2021, 13, 1926.	1.7	17
660	CAR-T cell therapy: current limitations and potential strategies. <i>Blood Cancer Journal</i> , 2021, 11, 69.	2.8	871
661	Metabolic barriers to cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2021, 21, 785-797.	10.6	245
662	Interfacing Biomaterials with Synthetic T Cell Immunity. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100157.	3.9	4
663	Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study. <i>Neuro-Oncology</i> , 2021, 23, 1569-1575.	0.6	20
664	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	1.7	27
665	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor Tâ€‘cell therapy. <i>British Journal of Haematology</i> , 2021, 193, 1060-1075.	1.2	13
666	Myelopathy Because of CAR-Tâ€‘Related Neurotoxicity Treated With Siltuximab. <i>Neurology: Clinical Practice</i> , 2021, 11, e944-e946.	0.8	3
667	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. <i>Future Oncology</i> , 2021, 17, 1269-1283.	1.1	20
668	Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain. <i>Gene Therapy</i> , 2023, 30, 411-420.	2.3	3

#	ARTICLE	IF	CITATIONS
669	Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5536.	1.8	17
670	Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 670088.	2.2	10
671	The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5352.	1.8	11
672	Recent Advances in Stimulus-Responsive Nanocarriers for Gene Therapy. <i>Advanced Science</i> , 2021, 8, 2100540.	5.6	60
673	Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 664688.	1.3	10
674	Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. <i>Cancers</i> , 2021, 13, 2712.	1.7	13
675	Neurological complications of cancer immunotherapy (CAR T cells). <i>Journal of the Neurological Sciences</i> , 2021, 424, 117405.	0.3	10
676	Palliative Radiotherapy for Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 650-658.	0.2	6
677	B-cell targeted therapies in pemphigus. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.1	1
678	Neuro-Oncologic Emergencies. <i>Neurologic Clinics</i> , 2021, 39, 545-563.	0.8	3
679	Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with <i>iggyBac</i> -modified CD19 CAR T cells. <i>Blood</i> , 2021, 138, 1504-1509.	0.6	86
680	Shaping of T Cell Functions by Trogocytosis. <i>Cells</i> , 2021, 10, 1155.	1.8	17
681	Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3002-3006.	3.3	26
682	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e355-e364.	2.2	43
683	Treatment resistance in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2151-2165.	3.3	44
684	Context matters in CAR T cell tonic signaling. <i>Nature Medicine</i> , 2021, 27, 763-764.	15.2	4
685	CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. <i>Frontiers in Neuroscience</i> , 2021, 15, 662064.	1.4	80
686	The antigen-binding moiety in the driver's seat of CARs. <i>Medicinal Research Reviews</i> , 2022, 42, 306-342.	5.0	21

#	ARTICLE	IF	CITATIONS
687	Ibrutinib improves the efficacy of anti-CD19 CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. <i>Cancer Science</i> , 2021, 112, 2642-2651.	1.7	23
688	Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine. <i>British Journal of Haematology</i> , 2021, 194, 158-167.	1.2	5
689	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2022, 22, 85-96.	10.6	315
691	Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?. <i>Inflammation Research</i> , 2021, 70, 651-663.	1.6	7
692	PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 599493.	2.2	8
693	Organoid models of the tumor microenvironment and their applications. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5829-5841.	1.6	27
694	Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland. <i>Advances in Therapy</i> , 2021, 38, 3427-3443.	1.3	14
695	Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials. <i>Leukemia and Lymphoma</i> , 2021, 62, 2169-2176.	0.6	5
696	The Potential Role of the Intestinal Microenvironment and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 670286.	2.2	16
697	Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. <i>Cancer Cell International</i> , 2021, 21, 262.	1.8	31
698	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. <i>Cancer Medicine</i> , 2021, 10, 5101-5109.	1.3	4
699	Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 506.e1-506.e10.	0.6	11
700	Nanotechnology synergized immunoengineering for cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 163, 72-101.	2.0	8
701	Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success. <i>Cancers</i> , 2021, 13, 2816.	1.7	8
702	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. <i>International Journal of Hematologic Oncology</i> , 2021, 10, IJH33.	0.7	11
703	Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29123.	0.8	15
704	A DL-4- and TNF \pm -based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1662-1676.	4.8	6
705	Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9577-9591.	2.9	19

#	ARTICLE	IF	CITATIONS
707	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 102.	6.9	64
708	New targets for CAR T therapy in hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101277.	0.7	9
709	EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. <i>Future Oncology</i> , 2021, 17, 2127-2140.	1.1	20
710	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. <i>Frontiers in Immunology</i> , 2021, 12, 681984.	2.2	32
711	Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products. <i>Pharmaceutical Research</i> , 2021, 38, 931-945.	1.7	18
712	Avoiding Stops and Overcoming Roadblocks: Considerations for Improving Patient Access to CAR-Based Cell Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e100-e104.	1.8	17
713	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19 ⁺ positive malignancies. <i>Oncology Reports</i> , 2021, 46, .	1.2	12
714	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6665.	1.8	11
715	CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. <i>Lung Cancer</i> , 2021, 157, 48-59.	0.9	16
716	Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1145-1154.	0.4	29
717	Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder. <i>Frontiers in Oncology</i> , 2021, 11, 709370.	1.3	11
718	Lines of therapy before autologous stem cell transplant and CAR ^T affect outcomes in aggressive Non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E386-E389.	2.0	4
719	Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. <i>Biomarker Research</i> , 2021, 9, 58.	2.8	22
720	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	15.2	273
721	Exploiting Single-Cell Tools in Gene and Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 702636.	2.2	21
722	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. <i>Haematologica</i> , 2022, 107, 1153-1162.	1.7	15
723	A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 715-727.	12.5	136
725	Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 698607.	1.3	25

#	ARTICLE	IF	CITATIONS
726	Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1â€² trial. <i>Leukemia</i> , 2022, 36, 189-196.	3.3	45
727	Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future. <i>Frontiers in Immunology</i> , 2021, 12, 718686.	2.2	19
728	EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations. <i>Neuro-Oncology</i> , 2022, 24, 313-325.	0.6	16
729	Chimeric antigen receptor Tâ€² cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. <i>Voprosy Onkologii</i> , 2021, 67, 350-360.	0.1	2
730	A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma. <i>Translational Oncology</i> , 2021, 14, 101085.	1.7	21
731	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. <i>Cancer Immunology Research</i> , 2021, 9, 1061-1070.	1.6	37
732	Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review. <i>Advances in Therapy</i> , 2021, 38, 4178-4194.	1.3	4
733	Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 558-570.	0.6	36
734	The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. <i>Cancers</i> , 2021, 13, 3596.	1.7	12
735	¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. <i>Molecular Imaging and Biology</i> , 2021, 23, 818-826.	1.3	8
736	Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 43-53.	0.6	8
737	New CARs on and off the road: challenges and new developments in CAR-T cell therapy. <i>Current Opinion in Pharmacology</i> , 2021, 59, 116-126.	1.7	2
738	Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 3912.	1.7	25
740	Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells. <i>Cytotherapy</i> , 2021, 23, 715-723.	0.3	11
741	Chimeric antigen receptor T-cells (CARs) in cancer treatment. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	1
742	Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 96-106.	2.0	11
743	Engineering-enhanced CAR T cells for improved cancer therapy. <i>Nature Cancer</i> , 2021, 2, 780-793.	5.7	60
744	Early ¹⁸ F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma. <i>Clinical Nuclear Medicine</i> , 2022, 47, e152-e153.	0.7	13

#	ARTICLE	IF	CITATIONS
745	VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. , 2021, 9, e002151.		16
746	“Built-in” PD-1 blocker to rescue NK ⁹² activity from PD-L1-mediated tumor escape mechanisms. <i>FASEB Journal</i> , 2021, 35, e21750.	0.2	5
747	TGF- β /IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8706.	1.8	16
748	A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients. <i>Value in Health</i> , 2022, 25, 47-58.	0.1	6
750	Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges. <i>Future Oncology</i> , 2021, 17, 3253-3270.	1.1	3
751	NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. , 2021, 9, e002866.		21
752	CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 910.e1-910.e11.	0.6	26
753	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
754	Targeted immunotherapies to consider for B Cell non-hodgkin lymphoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 317-332.	0.4	0
755	Production and Application of CAR T Cells: Current and Future Role of Europe. <i>Frontiers in Medicine</i> , 2021, 8, 713401.	1.2	15
756	Efficacy and safety of <sc>CD19</sc>-directed <sc>CAR</sc> cell therapies in patients with relapsed/refractory aggressive B<sc>cell</sc> lymphomas: Observations from the <sc>JULIET</sc>, <sc>ZUMA</sc>, and <sc>TRANSCEND</sc> trials. <i>American Journal of Hematology</i> , 2021, 96, 1295-1312.	2.0	107
757	CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2021, 385, 567-569.	13.9	175
758	The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T<sc>cell</sc> therapy in patients with large B<sc>cell</sc> lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 405-412.	1.2	10
759	The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. <i>Cancers</i> , 2021, 13, 4683.	1.7	9
760	Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. <i>Immunologic Research</i> , 2021, 69, 471-486.	1.3	8
761	Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. <i>JCO Oncology Practice</i> , 2022, 18, e193-e203.	1.4	0
762	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	0.6	52
763	Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. <i>Journal of Biological Chemistry</i> , 2021, 297, 101033.	1.6	12

#	ARTICLE	IF	CITATIONS
764	Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting. <i>Stem Cell Investigation</i> , 2021, 8, 18-18.	1.3	12
765	Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. <i>International Journal of Hematology</i> , 2021, 114, 544-553.	0.7	6
766	Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies. <i>Nature Communications</i> , 2021, 12, 5581.	5.8	8
767	Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 726134.	1.3	9
768	Recognition of Hematopoietic Stem Cell Transplantation and Cellular Therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focused Competence in Canada. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 702-706.	0.6	2
769	Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review. <i>Cancer Biology and Therapy</i> , 2021, , 1-7.	1.5	2
770	Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy. <i>Clinical Lung Cancer</i> , 2022, 23, 14-20.	1.1	4
771	Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases. <i>Frontiers in Oncology</i> , 2021, 11, 737645.	1.3	4
772	Cellules CAR-T: extension aux maladies auto-immunes en rhumatologie. <i>Revue Du Rhumatisme (Edition Tj ETQq0,0,0 rgBT /Qverlock 1</i>		
773	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. <i>The Cochrane Library</i> , 2021, 2021, CD013365.	1.5	18
774	Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. <i>Molecular Therapy</i> , 2021, 29, 2677-2690.	3.7	17
775	Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1373-1381.	1.4	4
776	Individual cell-based modeling of tumor cell plasticity-induced immune escape after CAR-T therapy. <i>Computational and Systems Oncology</i> , 2021, 1, e21029.	1.1	1
777	Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study. <i>Immunotherapy</i> , 2021, 13, 1261-1269.	1.0	3
778	Conditional control of chimeric antigen receptor T-cell activity through a destabilizing domain switch and its chemical ligand. <i>Cytotherapy</i> , 2021, 23, 1085-1096.	0.3	2
779	Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. <i>Blood Advances</i> , 2022, 6, 717-730.	2.5	22
780	Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 407-421.	1.4	1
781	Is There a Place for Chimeric Antigen Receptor T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?. <i>Arthritis and Rheumatology</i> , 2021, 73, 1954-1965.	2.9	28

#	ARTICLE	IF	CITATIONS
782	Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors. <i>Human Gene Therapy</i> , 2021, 32, 1011-1028.	1.4	14
783	CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?. <i>Cancers</i> , 2021, 13, 4664.	1.7	10
784	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. <i>Blood</i> , 2022, 139, 1026-1038.	0.6	67
785	CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. <i>Current Research in Translational Medicine</i> , 2021, 69, 103304.	1.2	12
786	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1403-1415.	5.1	222
787	HIV-specific CAR T cells return to the clinic. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	3
789	Advances in clinical immunotherapy for gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188615.	3.3	153
790	Synthetic receptors for logic gated T cell recognition and function. <i>Current Opinion in Immunology</i> , 2022, 74, 9-17.	2.4	7
791	Improving the safety of iPSC-derived T cell therapy. , 2022, , 95-115.		3
792	Cellular Therapy. <i>Organ and Tissue Transplantation</i> , 2021, , 741-761.	0.0	0
793	Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. <i>Oncimmunology</i> , 2021, 10, 1959102.	2.1	19
795	Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL. <i>Leukemia Research Reports</i> , 2021, 16, 100260.	0.2	6
796	Cancer Immunotherapy. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 1-41.	0.1	0
797	Nanomaterials to target immunity. <i>Advances in Pharmacology</i> , 2021, 91, 293-335.	1.2	3
798	Glycans as Targets and Mediators of T-Cell Immunotherapy. , 2021, , 508-518.		0
799	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 271.	1.7	39
800	Beyond the storm – subacute toxicities and late effects in children receiving CAR T cells. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 363-378.	12.5	37
801	Immune escape mechanism of B-cell malignancies on Anti-CD19 Chimeric Antigen Receptor T-cell treatment and solution. <i>E3S Web of Conferences</i> , 2021, 271, 03038.	0.2	0

#	ARTICLE	IF	CITATIONS
802	Infectious complications of CAR T-cell therapy: a clinical update. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110367.	1.1	28
803	Noninvasive Imaging of Cancer Immunotherapy. <i>Nanotheranostics</i> , 2021, 5, 90-112.	2.7	22
804	In Vitro Differentiation of T Cells from Murine Pluripotent Stem Cells. <i>Methods in Molecular Biology</i> , 2019, 2048, 131-141.	0.4	1
806	CAR T-Cells. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 215-233.	0.8	24
807	Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 178-188.	0.4	60
809	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
810	Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 645-660.	0.9	31
811	Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin's lymphoma. <i>JCI Insight</i> , 2019, 4, .	2.3	14
812	TGF- β 2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. <i>JCI Insight</i> , 2020, 5, .	2.3	195
813	Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. <i>JCI Insight</i> , 2020, 5, .	2.3	51
814	T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 1551-1565.	3.9	108
815	Immunotherapy of lymphomas. <i>Journal of Clinical Investigation</i> , 2020, 130, 1576-1585.	3.9	32
816	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. <i>Journal of Clinical Investigation</i> , 2019, 130, 673-685.	3.9	78
817	Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells. <i>Blood</i> , 2020, 135, 2425-2427.	0.6	22
818	Indolent lymphomas: pushing the pace with novel agents. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 279-286.	0.9	1
819	Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 487-493.	0.9	6
820	Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy. <i>Critical Reviews in Oncogenesis</i> , 2019, 24, 105-118.	0.2	8
821	Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma. <i>Translational Cancer Research</i> , 2018, 7, S510-S513.	0.4	19

#	ARTICLE	IF	CITATIONS
822	Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma. <i>Current Cancer Drug Targets</i> , 2019, 19, 681-687.	0.8	13
823	Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 1325-1339.	0.9	2
824	Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. <i>Immunotherapy</i> , 2020, 12, 1341-1357.	1.0	3
825	Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 1284-1315.	3.0	12
826	Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies. <i>Clinical Hematology International</i> , 2019, 1, 79.	0.7	15
827	Chimeric Antigen Receptor-Natural Killer Cells: The Future of Cancer Immunotherapy. <i>Ochsner Journal</i> , 2019, 19, 186-187.	0.5	17
828	Cytokines in CAR T Cell-associated Neurotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 577027.	2.2	110
829	The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities. <i>Cancers</i> , 2021, 13, 38.	1.7	17
830	Why Immunotherapy Fails in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 1-42.	0.2	5
831	CAR T cell therapy for gastric cancer: Potential and perspective (Review). <i>International Journal of Oncology</i> , 2020, 56, 889-899.	1.4	5
832	Efficacy and safety of second-generation CAR T cell therapy in diffuse large B cell lymphoma: A meta-analysis. <i>Molecular and Clinical Oncology</i> , 2020, 13, 33.	0.4	23
833	CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report. <i>Oncology Letters</i> , 2019, 18, 4415-4420.	0.8	24
834	Dual specific CD19/CD22-targeted chimeric antigen receptor T cell therapy for refractory diffuse large B cell lymphoma: A case report. <i>Oncology Letters</i> , 2020, 20, 21.	0.8	7
835	Adverse Events of Oncologic Immunotherapy and Their Management. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2019, 6, 212-226.	0.7	26
836	Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 8, .	0.2	3
837	Nanoparticle Systems Applied for Immunotherapy in Various Treatment Modalities. <i>Bioanalysis</i> , 2021, , 117-142.	0.1	0
838	Critical care management of chimeric antigen receptor T cell therapy recipients. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 78-93.	157.7	29
839	Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines. <i>Advanced Materials</i> , 2022, 34, e2103790.	11.1	81

#	ARTICLE	IF	CITATIONS
840	Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas. Current Treatment Options in Oncology, 2021, 22, 111.	1.3	6
841	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. Transplantation and Cellular Therapy, 2022, 28, 5-17.	0.6	4
842	Improving CAR T-Cell Persistence. International Journal of Molecular Sciences, 2021, 22, 10828.	1.8	44
843	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Advances, 2022, 6, 486-494.	2.5	25
844	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduction and Targeted Therapy, 2021, 6, 367.	7.1	31
845	Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma. Molecular Therapy, 2022, 30, 534-549.	3.7	20
846	The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. International Reviews of Immunology, 2022, 41, 649-668.	1.5	7
847	Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas. Transplantation and Cellular Therapy, 2021, 28, 30.e1-30.e1.	0.6	11
848	Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics. Molecular Therapy - Methods and Clinical Development, 2021, 23, 359-369.	1.8	7
849	Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo. Experimental Cell Research, 2021, 409, 112886.	1.2	15
851	Prise en charge des cellules CAR-T au sein des établissements de santé français : fabrication, distribution, et aspects réglementaires. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1431-1440.	0.0	1
852	Therapy for relapsed multiple myeloma. Panminerva Medica, 2018, 60, 174-184.	0.2	1
854	Immunological Approaches. Technik Im Fokus, 2019, , 307-324.	0.2	0
855	Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors. Methods in Molecular Biology, 2019, 2048, 27-39.	0.4	0
856	Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?. International Journal of Hematology-Oncology and Stem Cell Research, 0, , .	0.3	0
858	Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma. Korean Journal of Medicine, 2019, 94, 152-158.	0.1	0
861	Novel Agents in Primary Central Nervous System Lymphoma. , 2020, , 119-135.		0
862	Transformed Follicular Lymphoma. , 2020, , 135-163.		0

#	ARTICLE	IF	CITATIONS
863	Regional Gene Therapy for Cancer. , 2020, , 55-71.		0
864	Biopharmaceutical molecules. , 2020, , 31-68.		1
865	Endocrine Toxicities of Immunotherapy. , 2020, , 187-200.		0
869	Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. International Journal of Particle Therapy, 2020, 7, 13-20.	0.9	3
870	Systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy. Clinical Nutrition ESPEN, 2021, 46, 60-65.	0.5	3
871	4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. , 2021, 9, e003354.		32
872	Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells. Cancers, 2021, 13, 5435.	1.7	3
873	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 3978-3992.	0.8	121
874	CAR-T Cell Clinical Trials Experience “ Past, Present and Future. , 2020, , 303-375.		0
875	What a Clinical Hematologist Should Know about T Cells?. International Blood Research & Reviews, 0, , 20-32.	0.1	25
876	Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma. Therapeutic Advances in Hematology, 2021, 12, 204062072110531.	1.1	4
877	Therapy Response Imaging in Lymphoma and Hematologic Malignancies. Medical Radiology, 2020, , 177-200.	0.0	0
879	Gentherapie und nukleinsÄurebasierte Therapie. , 2020, , 85-97.		0
880	Neurological Toxicities of Immunotherapy. , 2020, , 223-242.		0
881	Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients. Frontiers of Medicine, 2021, , 1.	1.5	1
882	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert Review of Anticancer Therapy, 2021, 21, 1333-1353.	1.1	9
883	Sal mediterrÄinea, yogurt, genÄotica e immunoterapia. Acta Medica Costarricense, 2018, 60, .	0.1	0
884	A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. Aging, 2020, 12, 18741-18753.	1.4	19

#	ARTICLE	IF	CITATIONS
885	Immunotherapy in Pancreatic Cancer. Digestive Disease Interventions, 2020, 04, 351-357.	0.3	1
886	A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?. Archives of Pathology and Laboratory Medicine, 2021, 145, 704-716.	1.2	1
887	Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma. Translational Cancer Research, 2018, 7, S510-S513.	0.4	6
888	Fire in the Smoke: Battling Brain Tumors. Cerebrum: the Dana Forum on Brain Science, 2018, 2018, .	0.1	0
889	The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2018, 16, 375-386.	0.3	15
890	Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia. Journal of the Advanced Practitioner in Oncology, 2018, 9, 537-544.	0.2	6
891	Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?. International Journal of Hematology-Oncology and Stem Cell Research, 2019, 13, 102-107.	0.3	0
897	Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. Current Research in Translational Medicine, 2022, 70, 103320.	1.2	9
898	The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 362-372.	0.2	9
899	Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation. Molecular Imaging and Biology, 2021, 24, 235.	1.3	4
900	Born to survive: how cancer cells resist CAR T cell therapy. Journal of Hematology and Oncology, 2021, 14, 199.	6.9	59
901	Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells. , 2021, 9, e003176.		10
902	Commercialization of Investigational Cell Therapy Products. , 2022, , 161-178.		0
903	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma. Hematology, Transfusion and Cell Therapy, 2021, 43, S22-S29.	0.1	0
904	T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. Frontiers in Immunology, 2021, 12, 780442.	2.2	42
905	An NK-like CAR T cell transition in CAR T cell dysfunction. Cell, 2021, 184, 6081-6100.e26.	13.5	160
906	Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients. Cancers, 2021, 13, 6073.	1.7	15
907	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nature Medicine, 2021, 27, 2085-2098.	15.2	146

#	ARTICLE	IF	CITATIONS
908	CAR T Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 297-317.	0.8	4
909	Neurologic Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 417-429.	0.8	2
911	Off-the-Shelf CAR-T. <i>Cancer Drug Discovery and Development</i> , 2022, , 109-120.	0.2	2
912	Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. <i>Lung Cancer</i> , 2022, 165, 1-9.	0.9	15
913	Engineered T cells and their therapeutic applications in autoimmune diseases. <i>Zoological Research</i> , 2022, 43, 150-165.	0.9	6
914	Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy. <i>Translational Cancer Research</i> , 2020, 9, 7310-7322.	0.4	2
917	CAR-T cells, from principle to clinical applications. <i>Bulletin Du Cancer</i> , 2021, 108, S4-S17.	0.6	15
920	CAR-T cell: Toxicities issues: Mechanisms and clinical management. <i>Bulletin Du Cancer</i> , 2021, 108, S117-S127.	0.6	7
923	CD81 costimulation skews CAR transduction toward naive T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	6
924	Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. <i>BMC Cancer</i> , 2022, 22, 98.	1.1	15
925	Immunotherapeutic Strategies in Cancer and Atherosclerosisâ€”Two Sides of the Same Coin. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 812702.	1.1	2
926	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.3	27
928	Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering. <i>ACS Synthetic Biology</i> , 2022, 11, 1-15.	1.9	14
929	Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer. <i>Reviews in Medical Virology</i> , 2022, 32, e2325.	3.9	6
930	CARâ€”Ts: new perspectives in cancer therapy. <i>FEBS Letters</i> , 2022, 596, 403-416.	1.3	16
931	Engineering cell-based therapies. , 2022, , 271-285.		0
932	Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on â€œOff-the-Shelfâ€”T Cell Therapy Using iPSC Technology and Gene Editing. <i>Cells</i> , 2022, 11, 269.	1.8	10
933	CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 800110.	1.3	7

#	ARTICLE	IF	CITATIONS
934	Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	3
935	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 91-103.	5.1	236
936	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. <i>Neurological Research and Practice</i> , 2022, 4, 1.	1.0	9
937	Prognostic value of FDGâ€PET/CT response for patient selection before chimeric antigen receptorâ€Tâ€cells therapy in nonâ€Hodgkin lymphoma. <i>Hematological Oncology</i> , 2022, 40, 796-800.	0.8	6
938	The therapeutic potential of immune cell-derived exosomes as an alternative to adoptive cell transfer. <i>BMB Reports</i> , 2022, 55, 39-47.	1.1	15
939	Prospect of CAR T-cell therapy in acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 211-220.	1.9	4
940	Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. <i>Science Translational Medicine</i> , 2022, 14, eabg3072.	5.8	47
941	Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. <i>Oncolmmunology</i> , 2022, 11, 2033528.	2.1	19
942	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	0.8	160
943	Ex Vivo Model to Assess the Exposure of Patients to Plasticizers from Medical Devices during Pre-CAR-T Cellsâ€â€Apheresis. <i>Toxics</i> , 2022, 10, 79.	1.6	1
944	Future Developments in the Treatment of AL Amyloidosis. <i>Hemato</i> , 2022, 3, 131-152.	0.2	2
945	The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy. <i>Pharmaceuticals</i> , 2022, 15, 207.	1.7	5
946	The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 95.	0.1	0
947	Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. <i>European Journal of Inflammation</i> , 2022, 20, 1721727X2210787.	0.2	0
948	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	1.1	7
949	Neurologic complications of immune modulatory therapy. , 2022, , 537-551.		0
950	Molecular Immune Targeted Imaging of Tumor Microenvironment. <i>Nanotheranostics</i> , 2022, 6, 286-305.	2.7	11
951	Gene Transduction of Natural Killer Cells for Clinical Application. <i>Methods in Molecular Biology</i> , 2022, 2463, 311-328.	0.4	1

#	ARTICLE	IF	CITATIONS
953	Global Research Trends on the Treatment of Diffuse Large B-Cell Lymphoma: A Bibliometric and Visualized Study. <i>Journal of Cancer</i> , 2022, 13, 1785-1795.	1.2	1
955	CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future. <i>Frontiers in Immunology</i> , 2022, 13, 817296.	2.2	35
956	Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1525-1560.	1.5	53
957	Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas. <i>Journal of Personalized Medicine</i> , 2022, 12, 267.	1.1	4
958	When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies. <i>Frontiers in Oncology</i> , 2022, 12, 837995.	1.3	2
959	Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma. <i>Annals of Translational Medicine</i> , 2022, 10, 298-298.	0.7	7
960	Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. <i>Cancer Research Communications</i> , 2022, 2, 158-171.	0.7	8
961	A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. <i>Frontiers in Immunology</i> , 2022, 13, 840956.	2.2	30
962	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. <i>Nature Medicine</i> , 2022, 28, 713-723.	15.2	117
963	PSMA-targeting TGF β -insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 724-734.	15.2	171
964	Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3368.	1.8	6
965	Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy. <i>Cells</i> , 2022, 11, 994.	1.8	18
966	Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. <i>Oncolmmunology</i> , 2022, 11, 2055703.	2.1	8
967	Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19 chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden. <i>Hematological Oncology</i> , 2023, 41, 275-284.	0.8	6
968	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	0.6	56
969	In situ antigen modification-based target-redirection universal chimeric antigen receptor T (TRUE) Tj ETQq1 1 0.784314 rgBT /Overlock	6.9	9
970	CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 119.	3.5	167
971	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 951-972.	2.0	4

#	ARTICLE	IF	CITATIONS
972	Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges. <i>Frontiers in Oncology</i> , 2022, 12, 787108.	1.3	9
973	DLBCL 1Lâ€”What to Expect beyond R-CHOP?. <i>Cancers</i> , 2022, 14, 1453.	1.7	7
974	CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 834002.	1.3	8
975	Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 98.	7.1	19
976	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
978	A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. <i>British Journal of Haematology</i> , 2022, 198, 482-491.	1.2	8
979	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. <i>Expert Review of Hematology</i> , 2022, 15, 305-320.	1.0	25
980	The Effects of Chimeric Antigen Receptor (CAR) Hinge Domain Post-Translational Modifications on CAR-T Cell Activity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4056.	1.8	7
981	Immunotherapy-Related Acute Kidney Injury. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 429-437.e1.	0.6	5
982	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 367.	3.5	72
983	Applying Synthetic Biology with Rational Design to Natureâ€™s Greatest Challenges: Bioengineering Immunotherapeutics for the Treatment of Glioblastoma. <i>Immuno</i> , 2022, 2, 40-51.	0.6	0
984	Follicular Lymphoma. , 0, , .		1
985	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
986	Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 780145.	2.2	11
989	Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. <i>Nature Communications</i> , 2021, 12, 7200.	5.8	31
990	Acoustofluidic-mediated molecular delivery to human T cells with a three-dimensional-printed flow chamber. <i>Journal of the Acoustical Society of America</i> , 2021, 150, 4534-4547.	0.5	5
991	Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation. <i>Engineering</i> , 2022, 10, 30-43.	3.2	3
992	Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 798352.	1.3	7

#	ARTICLE	IF	CITATIONS
993	Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment. <i>Cancers</i> , 2022, 14, 141.	1.7	8
994	CAR T cell therapy in solid tumors: A review of current clinical trials. <i>EJHaem</i> , 2022, 3, 24-31.	0.4	57
995	Charting the tumor antigen maps drawn by single-cell genomics. <i>Cancer Cell</i> , 2021, 39, 1553-1557.	7.7	9
996	Chimeric Antigen Receptor T Cells, the Shock of the New*. <i>Critical Care Medicine</i> , 2022, 50, 157-160.	0.4	0
997	Cancer Therapy Targeting CD47/SIRP α . <i>Cancers</i> , 2021, 13, 6229.	1.7	20
998	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 171-187.	1.3	9
999	Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. <i>BMC Cancer</i> , 2022, 22, 393.	1.1	11
1000	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	2.8	6
1001	Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 930-939.	3.0	10
1002	Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases. <i>Gematologiya I Transfuziologiya</i> , 2022, 67, 8-28.	0.1	1
1003	Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e730-e737.	0.2	6
1004	A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 365.e1-365.e7.	0.6	8
1005	CAR T cell killing requires the IFN γ R pathway in solid but not liquid tumours. <i>Nature</i> , 2022, 604, 563-570.	18.7	150
1006	Comparison of Post-Transplantation Lymphoproliferative Disorder Risk and Prognostic Factors between Kidney and Liver Transplant Recipients. <i>Cancers</i> , 2022, 14, 1953.	1.7	2
1007	GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. <i>Leukemia</i> , 2022, 36, 1635-1645.	3.3	12
1014	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. <i>Cancer Cell</i> , 2022, 40, 494-508.e5.	7.7	54
1015	NextGen CARs: the race is on. <i>Blood</i> , 2020, 136, 1570-1571.	0.6	0
1024	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. <i>Cancer Treatment and Research</i> , 2022, 183, 161-184.	0.2	2

#	ARTICLE	IF	CITATIONS
1025	Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies. <i>Frontiers in Microbiology</i> , 2022, 13, 862270.	1.5	19
1026	Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. <i>Blood</i> , 2022, 140, 491-503.	0.6	32
1027	Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, 45.	6.9	43
1028	A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020. <i>Computers in Biology and Medicine</i> , 2022, 146, 105565.	3.9	9
1029	Treatment of indolent lymphoma. <i>Blood Research</i> , 2022, 57, S120-S129.	0.5	2
1030	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1195-1206.	1.9	18
1031	A novel adoptive synthetic <sc>TCR</sc> and antigen receptor (<sc>STAR</sc>) <sc>Tâ€Cell</sc> therapy for <sc>Bâ€Cell</sc> acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, 992-1004.	2.0	8
1032	Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. <i>Cell</i> , 2022, 185, 1745-1763.e22.	13.5	88
1033	Optimizing rAAV6 transduction of primary T cells for the generation of anti-CD19 AAV-CAR-T cells. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 113027.	2.5	2
1034	Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. <i>Cancer Letters</i> , 2022, 538, 215697.	3.2	16
1035	Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 2364-2374.	0.6	6
1037	Locally secreted BiTEs complement CAR Tâ€Cells by enhancing killing of antigen heterogeneous solid tumors. <i>Molecular Therapy</i> , 2022, 30, 2537-2553.	3.7	32
1038	Time 2EVOLVE: predicting efficacy of engineered T-cells â€“ how far is the bench from the bedside?. , 2022, 10, e003487.		13
1039	Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects <i>In Vivo</i> Expansion and Disease Response in Patients with Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 3378-3386.	3.2	15
1040	Recent advances in biomaterial-assisted cell therapy. <i>Journal of Materials Chemistry B</i> , 2022, 10, 7222-7238.	2.9	6
1041	Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. <i>Cytotherapy</i> , 2022, 24, 962-973.	0.3	6
1042	Anticalinâ€-based therapeutics: Expanding new frontiers in drug development. <i>International Review of Cell and Molecular Biology</i> , 2022, , 89-106.	1.6	3
1043	CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. <i>Cells</i> , 2022, 11, 1804.	1.8	1

#	ARTICLE	IF	CITATIONS
1044	Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies. <i>Hematological Oncology</i> , 2022, 40, 821-834.	0.8	3
1045	mRNA-based therapeutics: powerful and versatile tools to combat diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	160
1046	Barriers and solutions to improve access for chimeric antigen receptor therapies. <i>Immunotherapy</i> , 2022, 14, 741-753.	1.0	3
1047	Binding and Efficacy of Anti-Robo4 CAR-T Cells against Solid Tumors. <i>Biomedicines</i> , 2022, 10, 1273.	1.4	1
1048	Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 4-14.	1.8	5
1049	CAR-T Therapy in Clinical Practice: Technical Advances and Current Challenges. <i>Advanced Biology</i> , 2022, 6, .	1.4	2
1050	Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1051	Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1053	CAR T-cell therapy for solid tumors: Fatal attraction requires adhesion. <i>Med</i> , 2022, 3, 353-354.	2.2	1
1054	Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	0
1055	Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report. <i>Acta Haematologica</i> , 2022, 145, 537-541.	0.7	5
1056	Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	1
1057	Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 4657-4660.	2.5	11
1058	Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1059	Universal allogeneic CAR T-cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. <i>Molecular Therapy</i> , 2022, 30, 3155-3175.	3.7	21
1060	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). <i>HemaSphere</i> , 2022, 6, e745.	1.2	7
1061	Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies. <i>British Journal of Haematology</i> , 0, , .	1.2	2
1062	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	33

#	ARTICLE	IF	CITATIONS
1063	Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. <i>Annals of Oncology</i> , 2022, 33, 916-928.	0.6	30
1064	Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACTiVe-2 trial). <i>BMJ Open</i> , 2022, 12, e060431.	0.8	4
1065	Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy. <i>World Journal of Clinical Cases</i> , 2022, 10, 6555-6562.	0.3	2
1066	Stem cell transplantation for lymphoma. <i>Journal of Illusion</i> , 2022, 11, 140-147.	0.0	0
1067	Molecular Therapy in Myasthenia Gravis. <i>Touch Reviews in Neurology</i> , 2022, 18, 49.	0.1	0
1068	BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3748.	1.0	1
1070	Immunotherapy of sarcomas with modified T cells. <i>Current Opinion in Oncology</i> , 2022, 34, 362-370.	1.1	5
1071	Mechanisms of resistance to immune checkpoint inhibitors. <i>Cancer Science</i> , 2022, 113, 3303-3312.	1.7	12
1072	EBAG9 silencing exerts an immune checkpoint function without aggravating adverse effects. <i>Molecular Therapy</i> , 2022, 30, 3358-3378.	3.7	2
1073	A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2757-2769.	1.2	4
1074	Contribution of B cells to cortical damage in multiple sclerosis. <i>Brain</i> , 2022, 145, 3363-3373.	3.7	15
1075	Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 0, , 1-5.	0.6	0
1076	Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 4821-4830.	2.5	20
1077	Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. <i>WIREs Mechanisms of Disease</i> , 2022, 14, .	1.5	5
1078	Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	47
1079	Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. <i>Cancer Discovery</i> , 2022, 12, 2372-2391.	7.7	19
1080	CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1081	Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma. , 2022, 1, .		0

#	ARTICLE	IF	CITATIONS
1082	Current State of Cell Therapies for Gastrointestinal Cancers. Cancer Journal (Sudbury, Mass), 2022, 28, 310-321.	1.0	0
1083	Severe infections in recipients of cancer immunotherapy: what intensivists need to know. Current Opinion in Critical Care, 2022, 28, 540-550.	1.6	5
1085	Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-10.	0.5	3
1086	Understanding CAR T-Cell-tumor interactions: Paving the way for successful clinical outcomes. Med, 2022, 3, 538-564.	2.2	11
1087	A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 99-106.	1.2	2
1088	The Use of Immunotherapy for Treatment of Gynecologic Malignancies. , 0, , 105-127.		1
1089	CAR-NK Cells: A Chimeric Hope or a Promising Therapy?. Cancers, 2022, 14, 3839.	1.7	15
1090	CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. Biomedicines, 2022, 10, 1960.	1.4	5
1091	Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma. Bone Marrow Transplantation, 2022, 57, 1623-1625.	1.3	1
1092	Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 277.e1-277.e9.	0.6	9
1093	Application of nanotechnology in CAR-T-cell immunotherapy. Chinese Chemical Letters, 2023, 34, 107747.	4.8	5
1094	Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Frontiers in Immunology, 0, 13, .	2.2	20
1095	An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e1092-e1099.	0.2	3
1096	Emerging advances in engineered macrophages for tumor immunotherapy. Cytotherapy, 2022, , .	0.3	1
1097	Successful provision of CAR-T therapy during a pandemic: low SARS-CoV-2 infection rates and reduction in ICU admissions following modification of patient pathway. Leukemia and Lymphoma, 2022, 63, 3265-3267.	0.6	1
1098	Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor. Pharmacological Research, 2022, 184, 106454.	3.1	11
1099	A Soluble NK-CAR Mediates the Specific Cytotoxicity of NK Cells toward the Target CD20 ⁺ Lymphoma Cells. , 2022, 13, 1576.		1
1101	Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy. Science Translational Medicine, 2022, 14, .	5.8	14

#	ARTICLE	IF	CITATIONS
1102	CAR-T cell potency: from structural elements to vector backbone components. Biomarker Research, 2022, 10, .	2.8	14
1103	Transcriptional states of CAR-T infusion relate to neurotoxicity – lessons from high-resolution single-cell SOM expression portraying. Frontiers in Immunology, 0, 13, .	2.2	4
1104	N6-methyladenosine in hematological malignancies: a concise review. Current Opinion in Hematology, 0, Publish Ahead of Print, .	1.2	0
1105	Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment. Frontiers in Oncology, 0, 12, .	1.3	5
1106	Preliminary efficacy and safety of Relmacabtagene autoleucl (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial. American Journal of Hematology, 2022, 97, .	2.0	0
1107	Novel cellular therapies for hepatobiliary malignancies. Hepatobiliary and Pancreatic Diseases International, 2022, , .	0.6	1
1108	Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting. Experimental Hematology and Oncology, 2022, 11, .	2.0	8
1109	Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis. Journal of Oncology, 2022, 2022, 1-12.	0.6	1
1110	Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nature Medicine, 2022, 28, 1848-1859.	15.2	79
1111	Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy. Cancers, 2022, 14, 4700.	1.7	6
1112	Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. International Journal of Environmental Research and Public Health, 2022, 19, 12366.	1.2	17
1113	TCR β -CART therapy mediates high-precision targeting of malignant T-cell clones. Blood Advances, 2023, 7, 1885-1898.	2.5	4
1114	Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules, 2022, 12, 1303.	1.8	11
1115	Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes. International Reviews of Immunology, 0, , 1-19.	1.5	2
1116	Ultrasound-mediated Delivery of Natural Killer Cells with Microbubble for Cancer Treatment. , 2022, , .		0
1117	Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML. Biomedicines, 2022, 10, 2441.	1.4	4
1119	Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25Åyears. Journal of Biomedical Science, 2022, 29, .	2.6	8
1120	Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge. Transplantation and Cellular Therapy, 2023, 29, 34.e1-34.e7.	0.6	3

#	ARTICLE	IF	CITATIONS
1121	NK cell therapy in relapsed refractory multiple myeloma. <i>Clinical Immunology</i> , 2023, 246, 109168.	1.4	2
1122	Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 27-33.	0.6	10
1123	Clinical application of cell-based therapies opportunities and challenges. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	0
1124	CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1125	Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy. <i>Neurohospitalist</i> , The, 2023, 13, 53-60.	0.3	2
1126	HIV-Specific CAR T Cells with CD28 or 4-1BB Signaling Domains Are Phenotypically and Functionally Distinct and Effective at Suppressing HIV and Simian Immunodeficiency Virus. <i>ImmunoHorizons</i> , 2022, 6, 693-704.	0.8	2
1127	Macrophage immunotherapy: overcoming impediments to realize promise. <i>Trends in Immunology</i> , 2022, 43, 959-968.	2.9	18
1128	Comparison of Acoustofluidic and Static Systems for Ultrasound-Mediated Molecular Delivery to T Lymphocytes. <i>Ultrasound in Medicine and Biology</i> , 2023, 49, 90-105.	0.7	1
1129	A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone. <i>Blood Science</i> , 2022, 4, 211-213.	0.4	0
1130	Clinical implications of T cell exhaustion for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 775-790.	12.5	182
1131	The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
1133	Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. <i>Blood</i> , 2023, 141, 467-480.	0.6	33
1134	B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
1135	CAR T Cell Immunotherapy That Revolutionary Breakthrough in Human Oncology Treatment: A Review. <i>Pharmacology & Pharmacy</i> , 2022, 13, 483-515.	0.2	0
1136	Newest Approaches in Immunotherapy for Non-Hodgkin's Lymphoma. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 40-48.	3.0	0
1137	Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial. <i>BMJ Open</i> , 2022, 12, e065109.	0.8	3
1138	Population dynamics and gene regulation of T cells in response to chronic antigen stimulation. <i>International Immunology</i> , 2023, 35, 67-77.	1.8	0
1139	Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. <i>Annals of Medicine</i> , 2022, 54, 2950-2964.	1.5	5

#	ARTICLE	IF	CITATIONS
1140	Switchable targeting of solid tumors by BsCAR T cells. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	13
1141	Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy. Neuro-Oncology Advances, 2023, 5, .	0.4	1
1142	Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	1
1143	Infection Associated with the Use of CAR T Cells. , 2022, , 315-331.		0
1144	Immunotherapeutic Strategies for Glioma Treatment. , 2022, , .		0
1145	Holistic immunomodulation for small cell lung cancer. Seminars in Cancer Biology, 2023, 88, 96-105.	4.3	4
1146	Recent progress in cancer immunotherapy: Overview of current status and challenges. Pathology Research and Practice, 2023, 241, 154241.	1.0	8
1147	Rehabilitation of patients after CAR T-cell therapy. Experiences on 5 patients. Transplant Immunology, 2023, 76, 101770.	0.6	0
1148	Immunotherapy of Lymphoma. , 2022, , 1-24.		0
1149	Strategies to enhance CAR-T persistence. Biomarker Research, 2022, 10, .	2.8	15
1150	Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions. Frontiers in Immunology, 0, 13, .	2.2	2
1151	Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1406-1413.	3.3	7
1152	A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count. Journal of Translational Medicine, 2022, 20, .	1.8	4
1153	Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T cell therapy. Cancer, 2023, 129, 441-449.	2.0	5
1154	<sc>NR4A1</sc> mediates <sc>NK</sc> cell dysfunction in hepatocellular carcinoma via the <sc>IFN</sc> <sc>STAT1</sc> <sc>IRF1</sc> pathway. Immunology, 2023, 169, 69-82.	2.0	6
1155	Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell, 2022, 40, 1470-1487.e7.	7.7	11
1156	Dose response correlation for CAR-T cells: a systematic review of clinical studies. , 2022, 10, e005678.		15
1157	Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial. Bone Marrow Transplantation, 2023, 58, 288-294.	1.3	2

#	ARTICLE	IF	CITATIONS
1158	Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. <i>Cancers</i> , 2022, 14, 5983.	1.7	6
1159	Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 923-936.	1.5	6
1160	Chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1161	Phase I CAR-T Clinical Trials Review. <i>Anticancer Research</i> , 2022, 42, 5673-5684.	0.5	0
1162	Immunohistochemical Analysis of Common Cancer Antigens in Head and Neck Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 5751-5761.	0.5	0
1163	Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes. <i>Radiology and Oncology</i> , 2022, 56, 409-419.	0.6	2
1164	SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1165	Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1166	Mechanisms of CAR T cell exhaustion and current counteraction strategies. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	9
1167	Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1845-1860.	1.3	2
1168	CAR Exosome-Based Therapeutics. , 2023, , 1-14.		0
1169	Current state of CAR-T therapy for T-cell malignancies. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211430.	1.1	11
1170	Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1172	Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus. <i>Viruses</i> , 2023, 15, 202.	1.5	5
1173	Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1174	The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study. <i>EClinicalMedicine</i> , 2023, 56, 101779.	3.2	8
1175	Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies. <i>Blood</i> , 2023, 141, 877-885.	0.6	5
1176	Advancements in Cancer Immunotherapies. <i>Vaccines</i> , 2023, 11, 59.	2.1	8

#	ARTICLE	IF	CITATIONS
1177	PRECLINICAL MOUSE MODELS IN ADOPTIVE CELL THERAPIES OF CANCER. Slovenian Veterinary Research, 2022, 59, .	0.0	0
1178	Chimeric antigen receptor T (<scp>CARâ€T</scp>) cells: Novel cell therapy for hematological malignancies. Cancer Medicine, 2023, 12, 7844-7858.	1.3	15
1179	Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy. Doklady Biochemistry and Biophysics, 0, , .	0.3	1
1180	Impact of Precision Medicine in Oncology. Cancer Journal (Sudbury, Mass), 2023, 29, 15-19.	1.0	1
1181	Tumor immunology. , 2023, , 245-452.		0
1182	Immunotherapy using CAR T: What we have learned from trials and where we are heading. , 2023, , 369-384.		0
1183	Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6131-6138.	1.2	5
1184	Advancing CAR T cell therapy through the use of multidimensional omics data. Nature Reviews Clinical Oncology, 2023, 20, 211-228.	12.5	30
1185	Immunotherapy: Targeting Cancer Cells. Biological and Medical Physics Series, 2023, , 179-217.	0.3	0
1186	The adrenal stress response is an essential host response against therapy-induced lethal immune activation. Science Signaling, 2023, 16, .	1.6	0
1187	Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Advances, 2023, 7, 4528-4538.	2.5	7
1188	A secondâ€generation <scp>CD38â€CARâ€T</scp> cell for the treatment of multiple myeloma. Cancer Medicine, 0, , .	1.3	1
1189	Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy. Cytotherapy, 2023, 25, 986-992.	0.3	3
1190	Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer. Biomedicine and Pharmacotherapy, 2023, 162, 114609.	2.5	4
1191	Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. Biomedicine and Pharmacotherapy, 2023, 162, 114648.	2.5	1
1192	Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review. HemaSphere, 2022, 6, e802.	1.2	7
1194	Synapse-tuned CARs enhance immune cell anti-tumor activity. Nature Biotechnology, 2023, 41, 1434-1445.	9.4	12
1195	The potential role of the thymus in immunotherapies for acute myeloid leukemia. Frontiers in Immunology, 0, 14, .	2.2	4

#	ARTICLE	IF	CITATIONS
1196	FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects. <i>Cancers</i> , 2023, 15, 1063.	1.7	4
1197	CAR-T Cell Therapy: the Efficacy and Toxicity Balance. <i>Current Hematologic Malignancy Reports</i> , 2023, 18, 9-18.	1.2	15
1198	CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement. <i>Cancers</i> , 2023, 15, 1249.	1.7	8
1199	CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. <i>Cancers</i> , 2023, 15, 1414.	1.7	9
1200	Effect of Expression of Methylation Driver Gene ZC2HC1A on Prognosis of Hepatocellular Carcinoma and Its Association with Immune Infiltration. <i>Advances in Clinical Medicine</i> , 2023, 13, 2661-2674.	0.0	0
1201	Secretion of 4-1BB ligand crosslinked to PD-1 checkpoint inhibitor potentiates CAR T cell solid tumor efficacy. <i>Human Gene Therapy</i> , 0, , .	1.4	0
1203	Chimeric antigen receptor T cells therapy in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 2279-2296.	1.2	2
1204	Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2023, 20, 371-387.	1.6	8
1205	Novel pathophysiological insights into CAR-T cell associated neurotoxicity. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	4
1206	Future landscape for the management of membranous nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 1228-1238.	1.4	3
1207	Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2023, 55, 1031-1047.	1.3	1
1208	How I treat refractory/relapsed diffuse large B-cell lymphomas with <scp>CD19</scp>-directed <scp>chimeric antigen receptor</scp> T cells. <i>British Journal of Haematology</i> , 2023, 201, 396-410.	1.2	3
1209	Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. , 2023, 11, e006292.		5
1210	Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	2
1211	CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Valueâ€™s Worth. <i>Current Oncology</i> , 2023, 30, 4033-4040.	0.9	0
1212	Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. <i>Cancer Research Communications</i> , 2023, 3, 821-829.	0.7	9
1213	Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	4
1214	Long-term outcomes following CAR T cell therapy: what we know so far. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 359-371.	12.5	119

#	ARTICLE	IF	CITATIONS
1215	Recent advances in CAR T-cell therapy for lymphoma in China. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	1
1216	Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2023, 7, 4926-4935.	2.5	12
1217	Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes. <i>Cancer Management and Research</i> , 0, Volume 15, 367-375.	0.9	1
1218	Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome. <i>Pathology and Oncology Research</i> , 0, 29, .	0.9	1
1219	Targeted therapy. , 2023, , 205-411.		0
1220	CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement. <i>JACC: Case Reports</i> , 2023, 15, 101840.	0.3	0
1232	The major clinical components of cancer immunotherapy (modulating cell-mediated immune) Tj ETQq0 0 0 rgBT /Overlock 10 ₀ Tf 50 502		0
1242	Radiotherapeutic palliation of lymphoma. , 2024, , 209-216.		0
1243	Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 509-524.		0
1256	Learning from cancer to address COVID-19. <i>Biologia Futura</i> , 2023, 74, 29-43.	0.6	0
1277	Proximity-inducing modalities: the past, present, and future. <i>Chemical Society Reviews</i> , 2023, 52, 5485-5515.	18.7	5
1291	Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1292	Treatment of relapsed follicular lymphoma. , 2024, , 147-164.		0
1294	Recent Developments in Cancer Detection and Treatment. , 2023, , 1-10.		1
1306	Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors. , 2023, , .		0
1323	Immunoregulatory nanomedicine for respiratory infections. , 0, , .		0
1327	Plasmablastic Lymphoma. , 2023, , .		0
1335	Transposon-Based Manufacturing of Human CAR-T Cells. <i>Methods in Molecular Biology</i> , 2024, , 187-199.	0.4	0

#	ARTICLE	IF	CITATIONS
1338	Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy. Bone Marrow Transplantation, 2024, 59, 162-170.	1.3	0
1358	Biomaterials to enhance adoptive cell therapy. , 0, , .		0
1360	Therapeutic Targeting of B Cells and Plasma Cells with a Focus on Multiple Sclerosis and Other Autoimmune Conditions. , 2024, , 425-435.		0
1370	Strategies for HIV-1 elimination. , 2024, , 595-617.		0
1388	Adoptive T-Cell Therapy for the Treatment of Lung Cancer. , 2024, , 101-130.		0